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ABSTRACT OF DISSERTATION

INVESTIGATIONS OF S-GLUTATHIONYLATION OF BRAIN PROTEINS IN THE
PROGRESSION OF ALZHEIMER’S DISEASE AND OF A POTENTIAL
GLUTATIONE MIMETIC AS A TREATMENT OF ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by
neurofibrillary tangles, senile plaques and loss of synapses. Many studies support the
notion that oxidative stress plays an important role in AD pathogenesis. Previous studies
from our laboratory employed redox proteomics to identify oxidatively modified proteins
in the AD inferior parietal lobule (IPL). The proteins were consistent with AD pathology
and have been central to further investigations of the disease. The present study was
focused on the identification of specific targets of protein S-glutathionylation in AD,
early AD (EAD), and mild cognative impairment (MCI) using a redox proteomics
approach. In AD IPL we identified deoxyhemoglobin, α-crystallin B, glyceraldehyde
phosphate dehydrogenase (GAPDH), and α-enolase as significantly S-glutathionylated
relative to these brain proteins in control IPL. Both, GAPDH and α-enolase were also
shown to have reduced activity in the AD IPL. With further investigation gammaenolase, dimethylarginine dimethylaminohyrdolase (DDAH), Cathepsin D, and 14-3-3
gamma were identified as significantly S-glutathionylated in the EAD IPL. Alpha
enolase was also identified as significantly S-glutathionylated in MCI IPL. These results
provide a correlation in proteins S-glutathionylated in the progression of AD even in the
reversible conditions of amnestic MCI.
Amyloid beta-peptide (1-42) [Aβ(1-42)], one of the main component of senile
plaque, can induce in vitro and in vivo oxidative damage to neuronal cells through its
ability to produce free-radicals. The aim of this study was to investigate the protective
effect of the xanthate, D609, on Aβ(1-42)-induced protein oxidation using a redox
proteomics approach. D609 was recently found to be a free radical scavenger and
antioxidant. In the present study, rat primary neuronal cells were pretreated with 50 µM
of D609 followed by incubation with 10 µM Aβ(1-42) for 24 hours. In the cells treated
with Aβ(1-42) alone four proteins that were significantly oxidized were identified:

Glyceraldehyde 3-phosphate dehydrogenase, pyruvate kinase, malate
dehydrogenase, and 14-3-3 zeta. Pretreatment of neuronal cultures with D609 prior to Aβ
(1-42) protects all the identified oxidized proteins in the present study against Abeta(142)-mediated protein oxidation. Therefore, D609 may ameliorate the Aβ(1-42)-induced
oxidative modification.
KEYWORDS: Alzheimer’s disease, Redox Proteomics,
Glutathione, enolase, D609
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CHAPTER ONE
Introduction and Research Aims
The purpose of this dissertation research is to study aspects of the progression of
Alzheimer’s disease (AD) in order to gain insight into the initiators of the disease that
could lead to possible treatment options. AD is a progressive neurodegenerative disorder
that is characterized pathologically by senile plaques (SP), neurofibrillary tangles (NFT),
and synapse loss (Mirra et al. 1991; Selkoe 2001). The order of development of these
moieties with respect to the progression of AD is unknown as well as the initiating step
of the disease, so these present studies include samples from subjects with mild cognitive
impairment (MCI) a transitional stage prior to the development of AD, early-stage AD
(EAD) who were diagnosed with AD though still early in development, and late-stage
AD (LAD) that are subjects diagnosed with advanced AD (Petersen et al. 1999;
Markesbery et al. 2005). Analysis of these samples potentially provides insight into
aspects of the causative and responsive pathology of the disease.
Oxidative stress has been hypothesized to play a role in the development of AD
(Butterfield and Stadtman 1997; Markesbery 1997). An increase in reactive oxygen
species (ROS) can cause oxidation of proteins, lipids, DNA, and RNA (Butterfield and
Stadtman 1997). The oxidation of proteins often affects their function, interrupting
enzyme-substrate interactions within the cell as well as cell-cell communication, which
leads to cell death. The consequences of oxidative damage are found with the pathology
of AD, and have been identified in MCI progressing through to LAD (Hensley et al.
1998; Petersen et al. 1999). These current studies investigate the protein oxidation at
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specific stages of AD that correlate with other researcher’s work to give a more complete
picture of AD pathology.
Protein carbonyls are a marker of oxidized proteins. Previous studies in our
laboratory have shown that protein carbonyls are significantly increased in the AD and
MCI brain in comparison with the representative age-matched cognitively normal brain
(Butterfield and Stadtman 1997; Butterfield et al. 2001). Specific proteins have been
identified as having increased protein carbonyls in the AD and MCI brain such as
creatine kinase BB (CK-BB), glutamine synthetase (GS), γ-enolase, ubiquitin carboxyterminal hyrdolase 1 (UCH-1), and dihydropyriminidase related protein 2 (DRP-2)
(Castegna et al. 2002b; Castegna et al. 2002a). These prior studies continued to show
certain proteins are more succeptible to oxidation than others that results in altered
enzymatic activity. These consequences were in alignment with the pathology of AD
(Butterfield and Lauderback 2002; Butterfield et al. 2003; Butterfield et al. 2007). This
observation led to further hypothesis involving earlier stages of AD, and if the study of
oxidized proteins could provide insight into early pathology and development of AD.
Other types of protein oxidation are also of interest, particularly Sglutathionylation, as it is shown to be an early response to oxidation. The role of Sglutathionylation is not fully elucidated, but it is involved in signaling pathways in
response to shifts in the oxidative balance of the cells (Dalle-Donne et al. 2007). The
mechanism of S-glutathionylation is driven by the oxidation of glutathione making it
reactive with reduced cysteine residues on proteins forming a disulfide bond between the
cysteine and the glutathione (Dalle-Donne et al. 2003). This disulfide bond is a
reversible modification, thought to be protective against more damaging, irreversible
oxidation. The S-glutathionylation of proteins in the progression of AD from MCI to
2

LAD was hypothesized to give insight into the function of S-glutathionylation and the
initiators of AD.
The oxidation state of glutathione (GSH) varies with the oxidation state of the
cell, as reduced GSH has a thiol group, while oxidized glutathione (GSSG) is composed
of two molecules linked through a disulfide bond. Once oxidized GSSG can be reduced
back to GSH by glutathione reductase, which provides a recyclable mechanism for
stabilizing the oxidation state of the cell and reducing oxidative stress (Meister and
Anderson 1983). The enhancement or duplication of this mechanism could circumvent
the oxidative damage in the AD brain. D609 is a xanthate molecule that functions as a
glutathione mimetic, and so it is hypothesized that the treatment of D609 will reduce
amyloid beta (Aβ)-induced oxidative damage (Lauderback et al. 2003). This dissertation
will provide evidence that oxidation increases in the progression of the AD brain that
leads to oxidatively modified proteins, undergoing the post-translational modifications Sglutathionylation and carbonylation, which can be prevented with the increase of
glutathione mimetic, D609.

In summary, this dissertation will address the following questions:
1. Are proteins oxidatively modified in the progression of AD from MCI to LAD,
therefore potentially leading to protein dysfunction and cognitive impairment?
2. Are proteins S-glutathionylated in the progression of AD, giving insight into the
pathology of AD?
3. Does D609, as a glutathione mimetic decrease Aβ-induced oxidative damage?
4. Does D609 protect specific neuronal proteins that undergo Aβ-induced oxidative
damage instead of a global reduction of oxidation?
3

5. Could GSH play a crucial role in protecting the AD brain?

Copyright © Shelley Faye Newman 2008
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CHAPTER TWO
Background

2.1 Alzheimer’s Disease
Alzheimer’s disease (AD) was discovered in 1906 by the German physician
whose name it now carries, Alois Alzheimer. This neurodegenerative disorder is a
devastating disease that can begin with persistent forgetfulness progressing through
dementia and ultimately leading to death. AD currently affects 5 million Americans and
is the 6th leading cause of death (www.alz.org). AD is a devastating disease that has no
current FDA – approved treatment that reverses the progression or prevents the
development of AD. Current treatments lessen the symptoms and can slow the cognitive
decline, but often lose their effectiveness within a year. A factor in the limitations of the
therapeutic strategies for AD is that the initial event in the development of AD is
currently unknown.

2.1.1 Amyloid Beta Peptide
The amyloid-beta peptide theory of AD gives a possible explanation for the
development of AD (Butterfield 1997; Subramaniam et al. 1998; Varadarajan et al. 1999;
Yatin et al. 1999a; Yatin et al. 1999b; Butterfield 2002). Amyloid precursor protein
(APP) is a transmembrane protein produced in the brain, which is cleaved by α, β, and γsecretases producing amyloid-beta peptides including Aβ (1-42) (Selkoe 2001). The
production of Aβ (1-42) is increased in the AD brain through an increase in APP
concentration as well as an increase in γ-secretase activity. Aβ (1-42) induces oxidation
in proteins, lipids, DNA, and RNA (Butterfield et al. 1999; Yatin et al. 1999a; Butterfield
5

et al. 2002; Butterfield and Boyd-Kimball 2004). One hypothesis suggests that Aβ (142) inserts in the plasma membrane and adopts the helical form. The single methionine
residue of Aβ interacts with the carbonyl on the backbone of isoleucine at residue 31,
that facilitates a one – electron oxidation of Met, forming a cationic sulfuranyl free
radical ((Kanski et al. 2002a; Kanski et al. 2002b; Kanski et al. 2002c; Boyd-Kimball et
al. 2004b; Boyd-Kimball et al. 2004a, 2005).

2.1.2 Oxidatively Modified Proteins
The Aβ - centered free radical is positioned to oxidize the nearby polyunsaturated
fatty acids (PUFAs) producing alkenals such as 4-hydroxy-2-nonenal and acrolein.
Proteins with nucleophilic side chains such as lysine, cysteine and histidine undergo
Michael addition with alkenals resulting in an aldehyde on the protein side chain (Figure
2.1). This is a source of increased protein carbonyls, which is an oxidative posttranslational modification. Protein carbonyls can also be formed by the oxidation of the
protein backbone (Figure 2.2) or oxidation of specific amino acids. Protein carbonyls are
used as an index of protein oxidation as a picture of the global oxidation in the brain in
AD. Protein oxidation is not the only end product of oxidation, and post-translational
modifications generally can affect the enzyme function (Hensley et al. 1995;
Subramaniam et al. 1997; Yatin et al. 1999a; Aksenov et al. 2000). The investigation of
oxidized proteins also gives insight to the enzyme dysfunction in AD pathogenesis.
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Figure 2.1
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Figure 2.1: Formation of HNE – modified cysteine as an example of HNE undergoing
Michael addition by nucleophilic peptide side chains.
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Figure 2.2

Figure 2.2: Formation of protein carbonyls caused by free radical scission of the peptide
backbone. Figure modifid from Redox Proteomics.
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2.2 The Brain
As the information center to the entire body, the brain is a component of the
nervous system that uses electronic impulses to control motion, thought, and behavior.
There are six major regions of the brain; frontal lobe, parietal lobe, occipital lobe,
temporal lobe, cerebellum, and the brain stem (Figure 2.3). Each of these regions has
specific functions they control although some functions involve more that one brain
region. The frontal lobe is the area in the front of the brain that controls organization and
problem solving as well as behavior and emotion. The parietal lobe is located behind the
frontal lobe at the top of the brain. It is control of visio-spatial reasoning, sensory
control, and the ability to understand spoken and written language. The occipital lobe is
located in the back of the brain and processes all visual information. There are two
temporal lobes, one on each side of the brain behind the ear. The temporal lobe is
responsible for short-term, visual, and verbal memory. The cerebellum is located at the
bottom of the brain and it controls balance. The brainstem is located below the
cerebellum and connects the brain to the spinal cord.

9

Figure 2.3

Figure 2.3: The six major regions of the brain. Figure modified from the Alzheimer’s
Disease Association.
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2.2.1 Brain Regions Affected in AD
The AD brain has an overall reduction in brain mass, but some regions of the
brain are more severely affected in AD than others. Specifically, the temporal lobe that
contains the hippocampus and partietal lobe are the most significantly affected by the
degeneration of AD.

2.2.2 Neuron
The nervous system is comprised of two sections: the central nervous system
(CNS) comprised of the brain and spinal cord, and the peripheral nervous system (PNS)
comprised of the nerves connecting the CNS to the rest of the body. Within the nervous
system there are two main types of cells: glia and neurons. Glia are the more abundant
cells, but neurons are the cells critical for the nerve transmission.

2.2.2.1 Neurotransmission
The cell body, soma, of the neuron has two critical components projecting from
it: axon and dendrites. The axon is responsible for outgoing information in the neuron by
carrying impulses to the synapse between neurons. The synapse has three components:
the pre-synaptic axon, synaptic cleft, and postsynaptic dendrite. The dendrite receives
the impulse and it continues through to the next neuron (Figure 2.4). This
electrochemical impulse causes the release of a neurotransmitter from the pre-synaptic
terminal to the synaptic cleft, referred to as an action potential. When stimulated the
synaptic vesicle fuses with the cell membrane resulting in the release of a
neurotransmitter to the synapse.
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Figure 2.4

Figure 2.4: Neurotransmission of electrochemical impulse from pre-synaptic axon to
post-synaptic dendrite.
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The neurotransmitter binds to its receptor site on the post-synaptic region, which
then leads to an action potential in next neuron. The neurotransmitter is then either
degraded or recycled. These processes constitute neurotransmission. This action
potential is generated when a neuron is excited, but prevented when the neuron is
inhibited.

2.3 Oxidative Stress
Oxidative stress occurs due to an imbalance in the levels of pro-oxidants and antioxidants. This imbalance can be caused by disease, stress initiators, or environmental
factors. The condition of oxidative stress can be caused by both an increase in prooxidants or a decrease in anti-oxidants creating reactive oxygen species (ROS) and
reactive nitrogen species (RNS). ROS and RNS are highly reactive with biomolecules
including proteins, lipids, carbohydrate, DNA and RNA (Butterfield and Stadtman
1997). The markers of oxidative stress that are commonly used in biological samples
include: protein carbonyls and 3-nitrotyrosine for protein oxidation; thiobarbituric acid
reactive substance (TBARS), free fatty acid release, iso- and neuroprostane formation, 2propen-1-al (acrolein) and 4-hydroxy-2-trans-nonenal (HNE) for lipid peroxidation;
advanced glycation end products for carbohydrates; and 8-OH-2’-deoxyguanosine and 8OH-guanosine and other oxidized bases, and altered DNA repair mechanisms for DNA
and RNA oxidation.
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2.3.1 Free Radicals
A free radical is a compound with an unpaired electron. Mitochondria are the
most common source of free radicals within the cell since they are the location of the
electron transport chain (ETC). A small percentage of the electrons separated from
protons are leaked from the ETC and react with molecular oxygen producing superoxide
(Figure 2.6). Other radicals such as nitric oxide are naturally occurring, formed by nitric
oxide synthase, and used as a signaling molecule (Figure 2.6).

Figure 2.5
O2 + e-

O2 -

Figure 2.5: Formation of superoxide

2.3.1.1 Reactive Oxygen Species (ROS)
ROS are defined as molecules that contain oxygen and have a higher reactivity
than the ground state of molecular oxygen, O2. Superoxide (O2-), hydrogen peroxide
(H2O2), and hydroxyl radical (OH) are examples of ROS known to cause oxidative
damage in the brain (Halliwell 2006).
Superoxide is a free radical produced by electrons leaking in the electron
transport chain as discussed in section 2.3 of this dissertation. Superoxide is also
produced enzymatically by xanthine with xanthine oxidase. To minimize the oxidative
damage, superoxide dismutase (SOD) catalyzes the reaction of superoxide to water and
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hydrogen peroxide (Figure 2.7). Hydrogen peroxide is generally reduced to water by the
enzyme catalase. However, hydrogen peroxide (H2O2) can react with reduced metal ions
such as Fe2+ or Cu+ to produce hydroxyl radical and hydroxide anion (Figure 2.7).
Though hydrogen peroxide is not as reactive as superoxide, it can be dangerous since it
has the ability to react with molecules further from the location of its synthesis and
produces a hydroxyl radical that is highly toxic.

Figure 2.6
O2-

SOD

H2O2 + H2O

Figure 2.6 Disproportionation of superoxide catalyzed by Superoxide Dismutase

2.3.1.2 Reactive Nitrogen Species (RNS)
The nitrogen counterpart to ROS are RNS and are very reactive. Nitric oxide
(NO), peroxynitrite (OONO-), and nitrogen dioxide (NO2) are examples of common
RNS and can result in protein nitration. Nitric oxide is produced by nitric oxide
synthase, which has three isoforms: inducible (iNOS), endothelial (eNOS), and neuronal
(nNOS). All three are found in the brain and have been implicated in the increase in
oxidative damage in the AD brain. Nitric oxide is involved in cell signaling pathways,
immune response, and vasodilation. Nitric oxide has the ability to cross the plasma
membrane, which gives it a large range of effects. Glyeraldehyde – 3 – phosphate
dehydrogenase (GAPDH) has been shown to be a NO sensor (Hara et al. 2006).
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2.3.2 Oxidative Stress and AD
Oxidative stress has been implicated to play a crucial role in the pathogenesis of a
number of neurodegenerative disorders including AD (Butterfield 2002). Among all the
body organs, brain is particularly vulnerable to oxidative damage because of its high
utilization of oxygen, increased levels of polyunsaturated fatty acid (that are readily
attacked by free radicals), and relatively high levels of redox transition metal ions; in
addition, brain has relatively low levels of antioxidants (Markesbery 1997; Butterfield et
al. 2001; Butterfield et al. 2002; Butterfield and Lauderback 2002). The presence of iron
ion in an oxygen-rich environment can further lead to enhanced production of hydroxyl
free radicals and ultimately lead to a cascade of oxidative events.

2.3.3 Reactive Oxygen Species and Proteins
Some of the earliest oxidative modifications following an oxidative insult are
increased levels of toxic carbonyls, 3-nitrotyrosine (3-NT), and HNE (Smith et al. 1997;
Lovell et al. 2001; Butterfield et al. 2002; Butterfield and Lauderback 2002; Castegna et
al. 2003; Sultana et al. 2006b; Sultana et al. 2006a).
Protein oxidation could lead to aggregation or dimerization of proteins; in
addition, protein oxidation can also lead to unfolding or conformational changes in the
protein thereby exposing more hydrophobic residues to an aqueous environment. This
exposure may lead to loss of structural or functional activity and protein aggregation and
subsequent accumulation of the oxidized proteins as cytoplasmic inclusions, such as tau
aggregation in the form of tangles and amyloid-β aggregation as senile plaques, as
observed in Alzheimer’s disease (AD) (Stadtman and Berlett 1997; Butterfield and
Kanski 2001). The accumulation of oxidatively modified proteins may disrupt cellular
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functions by alterations in protein expression and gene regulation, protein turnover,
modulation of cell signaling, induction of apoptosis and necrosis, etc., which suggest that
protein oxidation could have both physiological and pathological significance
(Butterfield and Stadtman 1997; Hensley et al. 2000; Naoi et al. 2005; Abdul and
Butterfield 2007). In our laboratory, we used redox proteomics analyses to identify
specific oxidatively modified brain proteins in neurodegenerative diseases and models
thereof [10, 12, 13, 32-41].

2.3.3.1 Formation of Protein Carbonyls
Protein carbonyl groups are generated by direct oxidation of certain amino acid
side chains (i.e., Lys, Arg, Pro, Thr, and His) (Figure 2.2), peptide backbone scission,
Michael addition reactions of His, Lys, and Cys residues with products of lipid
peroxidation (Figure 2.3), or glycol-oxidation of Lys amino groups (Berlett and Stadtman
1997; Butterfield and Stadtman 1997; Stadtman and Levine 2003; Dalle-Donne et al.
2005; Dalle-Donne et al. 2006). Protein carbonyls are relatively stable and hence are
widely used as markers to assess the extent of oxidation of proteins both in in vivo and in
vitro conditions (Berlett and Stadtman 1997; Butterfield 1997; Stadtman and Levine
2003; Dalle-Donne et al. 2006). The levels of protein carbonyls can be determined
experimentally by derivatization of the carbonyl groups with 2,4-dinitrophenylhydrazine
(DNPH), followed by spectroscopic or immunochemical detection of the resulting
hydrazone product (Levine et al. 1994; Butterfield and Stadtman 1997; Dalle-Donne et
al. 2006).
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2.3.3.2 Formation of 3 – Nitrotyrosine
In addition to direct effects, oxidative stress could also stimulate additional
damage in brain via the overexpression of inducible nitric oxide synthase (NOS: iNOS)
and the action of constitutive neuronal NOS (nNOS) that increase the production of nitric
oxide (NO.) via the catalytic conversion of arginine to citrulline. Nitric oxide reacts with
superoxide anion (O2.-) at a diffusion controlled rate to produce peroxynitrite (ONOO-).
Peroxynitrite is highly reactive with a half-life of less than a second, and can undergo a
variety of chemical reactions depending upon its cellular environment, the presence of
CO2, and the availability of reactive targets forming modifications such as 3-NT
(Koppenol et al. 1992; Murphy et al. 1998). 3-Nitrotyrosine is a covalent protein
modification that has been used as a marker of nitrosative stress under in a variety of
disease conditions (Beckman and Koppenol 1996; Ischiropoulos 2003). Peroxynitrite
can also react with sulfhydryl compounds intracellularly due to the high concentration of
free thiols within the cell (Radi et al. 1991). Sulfhydryls can also react via Snitrosylation with NO to form a nitrosothiol (RSNO). Cysteine residues are
preferentially nitrosylated due to favorable reaction kinetics (Gow et al. 1996; Broillet
1999).

2.3.4 Lipid Peroxidation
Amplified lipid peroxidation has been described in several neurodegenerative
diseases including AD (Lovell et al. 1995; Markesbery and Lovell 1998; Lauderback et
al. 2001; Lovell et al. 2001). Analysis of AD brains demonstrates an increase in free
HNE in amygdala, hippocampus, and parahippocampal gyrus of the AD brain when
compared with age-matched controls (Markesbery and Lovell 1998). This increased
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alkenal concentration corresponds with the regions showing the most striking
histopathologic alterations in AD. A significant elevation of free HNE in ventricular
cerebrospinal fluid (CSF) and serum provides a potential biomarker for AD (Lovell et al.
1997; McGrath et al. 2001). Protein-bound HNE, which is indication of Michael
addition of HNE to proteins, is elevated in AD (Sayre et al. 1997; Lauderback et al.
2001; Butterfield et al. 2002; Butterfield and Lauderback 2002). HNE is elevated in
neurons treated with Aβ (1-42) (Mark et al. 1997; Lauderback et al. 2001; Boyd-Kimball
et al. 2004b). Protein–bound HNE alters conformation and function of proteins
(Subramaniam et al. 1997; Lauderback et al. 2001) . In AD brain protein–bound HNE is
found on the glutamate transporter (Glt-1 or EAAT), glutathione–S-transferase (GST),
and mulit-drug resistant protein (MRP-1) (Lauderback et al. 2001; Sultana and
Butterfield 2004). Thus processes related to excitotoxicity may be facilitated, while
processes related to removal of HNE from neurons (via GST and MRP1) may be
compromised.

2.4 Glutathione
Potential antioxidant systems include a low molecular weight thiol compound,
glutathione (GSH), which is present at high concentrations (0.5–10 mM) in brain cells is
ubiquitously distributed in different cellular compartments, which results in different
subcellular redox environments (Halliwell and Gutteridge 1999; Sies 1999). GSH is
composed of three amino acids (γ-glutamyl-cysteinyl-glycine), in which the thiol on the
cysteine plays an important role in maintaining the cellular redox state under oxidative
stress (Figure 2.7). GSH with the reduced thiol is the predominant form.
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Figure 2.7

Figure 2.7: Representation the oxidation – reduction reaction between GSH and GSSH
as well as the addition of glutathione to a protein.
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2.4.1 Glutathione Synthesis
The majority of GSH is located in the cytosol (1–10 mM) with a small percentage
in the mitochondria (5–10 mM), yet all cellular GSH is synthesized within the cytoplasm.
GSH is synthesized from its individual amino acids within the cell. The synthesis occurs
in two consecutive reactions. L-cysteine is first coupled through a peptide bond with the
amide on L-glutamate side chain, catalyzed by γ-glutamylcysteine ligase at the expense
of ATP in the presence of Mg. γ-Glutamylcysteine undergoes a reaction with glycine
catalyzed by GSH synthetase ligase at the expense of ATP in the presence of Mg
producing GSH. Cysteine is the limiting reactant in the synthesis of GSH since it is
available at micromolar concentrations due to its toxicity, while glutamate and glycine
are available at millimolar concentrations {Cooper, 1997 #89}.

2.4.2 Role of Glutathione
The general mechanism of GSH protection comes from the ability of GSH to
form a disulfide (GSSG) when oxidized, which can then be reduced back to GSH by
glutathione reductase (Figure 2.9). This process makes GSH a recyclable antioxidant
mjjolecule. The GSH:GSSG is maintains the specific redox homeostasis, and is
interrelated with other redox pairs that are maintained within physiologic ranges for
oxidation and reduction (Figure 2.8) . These redox pairs include NADPH/NADP+,
reduced thioredoxin/oxidized thioredoxin (Trx(SH)2/TrxSS), and cysteine/cystine
couples (Jones et al. 2004; Maher 2006). When these redox couples are forced out of the
physiologic range, adverse consequences result.
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Table 2.1

The Concentration Ratio of GSSG to GSH Directly Affects Cell Potential
GSSG:GSH1
1:10
1:05
1:01
5:01
10:01
1
2

Cell Potential (V)2
0.296
0.207
0.000
-0.207
-0.296

This ratio is based on relative concentrations.
Cell potential calculated using the Nernst Equation
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2.4.3 S-Glutathionylation
Previous research shows that moderate oxidation can result in the formation of a
mixed disulfide bond between protein cysteine side chains (PSH) and GSH to form
glutathionylated proteins (PSSG), (Figure 2.7) (Dalle-Donne et al. 2003).
Glutathionylation is a reversible post-translational modification; from which the release
of GSH can be catalyzed enzymatically by glutaredoxin (GRx), a thioltransferase
(Chrestensen et al. 2000; Cotgreave et al. 2002; Shenton et al. 2002). Inflammatory
response is connected with redox signaling and ROS. ROS initiate inflammatory signal
transduction leading to cytokine production, promoting glutathionylation of many
proteins, and possibly activate or induce expression of GRx. β-amyloid is a ligand for
the receptor for advanced glycation end products (RAGE) (van Beijnum et al., 2008).
RAGE activates the NFκB pathway, which involves a particularly abundant the group of
proteins that are subject to modulation by glutathionylation, HS60 and HS70 that have
been shown to be glutathionylated in T-lymphocytes in response to oxidative stimuli
(Fratelli et al., 2002). Elevated GRx has been reported in Alzheimer’s disease of postmortem brains (Akterin et al., 2006).
The cell could potentially utilize S-glutathionylation as a form of redox
regulation of protein function and activity (Klatt and Lamas 2000; Casagrande et al.
2002; Dalle-Donne et al. 2003).
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CHAPTER THREE
Methods

3.1 Sample Preparation
Brain samples were sonicated and suspended in 10mM HEPES buffer (pH 7.4)
containing 137mM NaCl, 4.6mM KCl, 1.1mM KH2PO4, 0.1mM EDTA, and 0.6mM
MgSO4 as well as proteinase inhibitors: leupeptin (0.5 mg/mL), pepstatin (0.7µg/mL),
type II S soybean trypsin inhibitor (0.5µg/mL), and PMSF (40 µg/mL). Homogenates
were centrifuged at 14,000×g for 10 min to remove debris.

3.1.1 Bicinchoninic acid (BCA) Protein Assay
The protein concentrations of the supernatant in this dissertation research was
determined using BCA protein assay (Pierce, Rockford, IL, USA). This assay uses the
Biuret reaction, protein-mediated reduction of Cu2+ to Cu+ by the peptide bond and
amino acids. When reduced, Cu+ forms a complex with BCA that absorbs at 562 nm
(Figure 3.1). A protein standard, bovine serum albumin (BSA) with Beer’s law is used
to calculate the concentration of protein samples.
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Figure 3.1

Figure 3.1: Protein reduces Cu2+ to Cu+ and reacts with bicinchoninic acid to form a
complex that is visible at 562 nm.
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3.2 Two – Dimensional Gel Electrophoresis
3.2.1 Sample Preparation
From each sample 150 µg of protein were aliquoted and dissolved in rehydration
buffer containing 8 M urea, 2% CHAPS, 0.2% (v/v) biolytes, and bromophenol blue. The
samples were sonicated three times for 20 s on ice and then applied to the IPG
Readystrip (pH 3-10) from Bio-Rad (Hercules, CA).

3.2.2 Isoelectric Focusing
Proteins were loaded onto the strip via active rehydration that was carried out for
16 h at 50 V and 20°C using the protean IEF cell (Bio-Rad). Isoelectric focusing was
then carried out at 20°C as follows: 800 V for 2 h linear gradient, 1200 V for 4 h of slow
gradient, 8000 V for 8 h of linear gradient, 8000 V for 10h of rapid gradient. Separating
the proteins according to their isoelectric point, the pH at which the compound is neutral
(Figure 3.2). The strips were stored at -80°C until second dimensional separation was
performed.
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Figure 3.2

Figure 3.2: Separation of proteins using 2D-PAGE. Proteins are first separated by their
isoelectric point by IEF, and then by molecular mobility using SDS-PAGE.
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3.2.3 SDS – PAGE
Gel strips were equilibrated before second dimension for 15 min in 50 mM TrisHCl (pH 6.8) containing 6 M urea, 1% (m/v) SDS, and 30% (v/v) glycerol. The gel strips
were then placed in the linear gradient precast Criterion Tris-HCl gels (8-16%, Bio-Rad)
to perform the second dimension electrophoresis. Precision protein standards (Bio-Rad)
were run along the sample at 200 V for 65 min. The gels were fixed in a solution
containing 10% (v/v) methanol and 7% (v/v) acetic acid for 20 min and then stained
overnight at room temperature with agitation in 50 ml SYPRO Ruby gel stain (Bio-Rad,
Hercules, CA). Sypro stain identifies proteins with a sensitivity up to 9 ng.

3.3 Two-Dimensional Western Blotting
3.3.1 Gel Transfer
For immunoblotting analysis, electrophoresis was carried out as stated in the
above section. The gels were transferred to a nitrocellulose membrane using the
Transblot-BlotSD Semi-Dry Transfer Cell at 45 mA per gel for 2 h.

3.3.2 Immunochemical Detection
The membranes were blocked with 2% bovine serum albumin (BSA) in PBS
containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBST) overnight at 4
°C. The membranes were incubated with rabbit monocolonal anti-GSH (Virogen,
Watertown, MA) (1:10) in PBST for 2 h with gentle rocking at room temperature. The
membranes were then washed three times for 5 min with PBST followed by incubation
with anti-rabbit alkaline phosphatase secondary antibody (1:3000) in PBST for 2 h at
room temperature. The membranes were then washed three times for 5 min with PBST
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and developed with SigmaFast tablets [5-bromo-4-chloro-3-indolyl phosphate/nitro blue
tetrazolium (BCIP/NBT)]. Blots were dried and scanned with Adobe Photoshop.

3.4 Image Analysis
The gels and nitrocellulose membranes were scanned by Scanjet 3300C Hewlett
Packard, Palo Alto, CA) and UV transilluminator (λex= 470nm, λem= 618nm) (Molecular
Dynamics, Sunnyvale, CA) respectively and saved in a TIFF format. PD Quest software
(Bio-Rad) was then used to compare the protein expression by 2D-gels and
immunoreactivity by 2D-blots. Average mode of background subtraction was used to
normalize intensity value, which represents the amount of protein (total protein on gel
and oxidized protein on oxyblot) per spot. After spots had been matched, the dataset was
obtained from the normalized intensity of each protein spot from the control, Aβ (1-42),
and D609 + Aβ (1-42) gels and oxyblots. In order to allow for protein concentration
changes the spot intensity values obtained on the blots are divided by the spot intensity
value on the gels to get the level of specific protein carbonyls. These, in turn, are
analyzed for significance using Student’s t-test.

3.5 In-Gel Trypsin Digestion
Samples were prepared according to (Thongboonkerd et al. 2002). Based on the
data obtained from image analysis, the protein spots that showed a significant increase in
oxidation due Aβ (1-42) and protection by D609 were excised from gel with a clean
razor blade and transferred into a clean 1.5 ml microcentrifuge tubes. The gel pieces were
washed with 0.1M ammonium bicarbonate (NH4HCO3) for 15 min at room temperature
under a flow hood, followed by addition of acetonitrile and incubation at room
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temperature for 15 min. The solvents were removed and the gel pieces were allowed to
dry. The gel pieces were incubated with 20 µl of 20 mM DTT in 0.1 M NH4HCO3 and
incubated for 45 min at 56°C. The DTT solution was removed and 20 µl of 55 mM
iodoacetamide (IA) in 0.1 M NH4HCO3 was added and incubated for 30 min in the dark
at room temperature. The liquid was removed and the gel pieces were incubated with 200
µl of 50 mM NH4HCO3 at room temperature for 15 min. Acetonitrile was then added to
the gel pieces for 15 min at room temperature. The solvents were removed and the gel
pieces were allowed to dry for 30 min. The gel pieces were rehydrated with 20 ng/µl
modified trypsin (Promega, Madison, WI) in 50 mM NH4HCO3. The gel pieces were cut
into small pieces and incubated while shaking overnight (~18 h) at 37°C.
3.6 Mass Spectrometry
The mass spectra of the sample were determined by a Tof-Spec 2E (Micromass, UK)
MALDI-TOF mass spectrometer operated in reflectron mode. One microliter of trypsindigested protein was mixed with 1 µl α-cyano-4-hydroxy-trans-cinnamic acid (10 mg/ml
in 0.1% TFA:ACN, 1:1, v/v) directly on the target and allowed to dry at room
temperature. The sample spot was then washed with 1µl of 1% TFA solution for
approximately 60 s. The TFA droplet was gently blown off the sample spot with
compressed air. The resulting diffuse sample spot was recrystallized (refocused) using 1
µl of a solution of ethanol:acetone:0.1% TFA (6:3:1). Reported spectra are a summation
of 100 laser shots. External calibration of the mass axis, used for acquisition
and internal calibration using either trypsin autolysis ions or matrix clusters were applied
post acquisition for accurate mass determination.
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3.6.1 Peptide Sequence Analysis
The MALDI spectra from the tryptic fragments used for protein identification were
searched against the entire NCBI and SwisProt protein databases using the MASCOT
search engine (http://www.matrixscience.com). Peptide mass fingerprinting uses the
assumptions that peptides are monoisotopic, oxidized at methionine residues, and
carbamidomethylated at cysteine residues and also allows for up to one missed trypsin
cleavage. Mass tolerance of 150 ppm was the window of error allowed for matching the
peptide mass values. Probability-based MOWSE scores were estimated by the
comparison of search results against estimated random match population and were
reported as 10*log10(p), where p is the probability that the identification of the protein
is not correct. MOWSE scores greater than 59 were considered to be significant (p <
0.05). Protein identifications were determined to be in the expected size and pI range
based on position in the gel. Previous proteomics analysis of AD brain proteins from our
laboratory were verified in some cases by immunochemical methods. Thus, we are
confident in the correct identity of the proteins that were identified in this paper.
3.7 Enzymatic Activity
The specific activities of GAPDH and α-enolase were determined using a
protocol outlined by the supplier [Sigma Aldrich (St. Louis, MO)]. The same age-match
control (n=5) and AD (n=5) samples were used in this analysis as were used in
proteomics study. Proteins were precipitated with the addition of cold 100%
trichloroacetic acid (TCA) for a final concentration of 15%. The samples were then
centrifuged at 14,000 × g and 4°C for 2 min. The resulting pellet was then washed with
500 µl of 1:1 (v/v) ethyl acetate/ethanol. Centrifugation and washing was repeated three

31

times to remove any remaining lipids. The protein sample was then dissolved in100 mM
triethylamine buffer (pH 7.4) for a final concentration of 0.750 µg/µl.

3.7.1 Activity of GAPDH
To determine the activity of GAPDH 5 µg of protein was added to an assay
mixture (100 mM 3-phosphoglyceric acid, 200 u/ml 3-phosphoglyceric phosphokinase,
200 mM cysteine, 100mM MgSO , 34mM ATP, 7.0mM β-NADH) in a UV-transparent
4

microtiter plate (Corning, MA). The change in absorbance at 340 nm was monitored
during a five minute period using a powerwave X plate reader (Bio-Tek Instrument Inc.
Winooshi, VT).

3.7.2 Activity of Enolase
To analyze the activity of α-enolase 5 µg of protein sample was added to an assay
mixture (56 mM 2-phosphoglycerate, 20 mM ADP, 700 u/ml pyruvate kinase, 7 mM βNADH, 1000 u/ml L-lactic dehydrogenase) in a UV-transparent microtiter plate
(Corning, MA). The decrease in absorbance 340 nm was recorded over five minutes
using a powerwave X plate reader (Bio-Tek Instrument Inc. Winooshi, VT).
3.8 Statistical Analysis
The comparison of protein levels and protein specific carbonyl levels were analyzed by
two-tailed Student’s t-tests, as generally used for proteomics analysis. A value of p <0.05
was considered statistically significant. A similar statistical analysis is usually used for
proteomics data analysis. Only the statistically significant comparisons between the
untreated control and Aβ (1-42)-treated neurons as well as between the D609 followed
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by Aβ (1-42)-treated neurons and only Aβ (1-42)-treated neurons were subjected to
proteomics analysis.

Copyright © Shelley Faye Newman 2008
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CHAPTER FOUR
Chapter Four: Protective effect of the xanthate, D609, on Alzheimer's Aβ peptide
(1-42)-induced oxidative stress in primary neuronal cells*
4.1 Introduction
Alzheimer’s disease (AD) neuropathology is characterized by loss of synapses
and the presence of amyloid plaques and neurofibrillary tangles. Amyloid plaques have a
central core of amyloid β-peptide [Aβ (1–42)]. The exact mechanism by which Aβ (1–
42) causes induced neurotoxicity[1 – 4] is not known, but a number of previous studies
from our laboratory and others have shown that the oxidative stress is induced by Aβ(1–
42), assessed by excessive formation of reactive oxygen species and reactive nitrogen
species (ROS/RNS) [5 – 9]. ROS/RNS causes tissue damage resulting from a wide
variety of insults like protein oxidation, lipid peroxidation, DNA and RNA oxidation and
neuronal death [5,6,8,10]. Oxidative modification of proteins in vivo may affect a
variety of cellular functions involving proteins: receptors, signal transduction
mechanisms, transport systems and enzymes.
4.1.1 Glutathione
Glutathione (GSH) is the major intracellular thiol, participating in cellular redox
reactions and thioether formation, and a decreased level of GSH may severely impair
normal cellular functions [11,12]. Further, it has been shown that GSH levels are
decreased in specific regions of the central nervous system of subjects affected by AD,
and this may contribute to the oxidative stress mediated neuronal cell loss [6,7,13 – 15].
An imbalance in cellular defense systems may contribute to AD pathology and dementia
*

This research was carried out in collaboration with Drs. Rukhsana Sultana and Hafiz
Mohammad Abdul.
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[6,7]. One of the ways to combat the toxic effects of Aβ (1–42) is to augment or
potentiate endogenous oxidative defense capacity through dietary or pharmacological
intake of antioxidants [16,17]. Therefore, the protective efficacy of tricyclodecan-9-ylxanthogenate (D609), a GSH mimetic [23], was tested against Aβ (1–42)-induced
oxidative stress in primary neuronal culture.
4.1.2 D609
D609 is an inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC)
[24,25]. This xanthate has been reported to protect against oxidative damage induced by
ionizing radiation and also shows antiviral and anti-tumor activity [26,27]. Previous
studies from our laboratory and others have reported the GSH mimetic function of D609
[23]. For example, D609 forms a disulfide upon oxidation, which is reduced to the
xanthate by GSH reductase, an enzyme that converts oxidized GSH (GSSG) to GSH.
The importance of the thiol in D609’s antioxidant ability was determined by methylating
the thiol, blocking its ability to form disulfide bonds. D609 also has the ability to
scavenge hydroxyl radicals and hydrogen peroxide [23,28]. In addition, D609 binds to
and thus detoxifies reactive alkenals, thereby preventing the latter from damaging
synaptosomes [23].
This present study was designed to study the protective effect of D609 against Aβ
(1–42) – induced oxidative damage in neuronal culture. The results are consistent with
the notion that D609 may be acting like GSH, thereby protecting the cells against Aβ (1–
42) – induced oxidative stress.
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4.2. Experimental Procedures
4.2.1 Chemicals
All chemicals were purchased from Sigma–Aldrich (St. Louis, MO, USA) unless
stated otherwise. The oxidized protein detection kit was purchased from Intergen
(Purchase, NY) and D609 from Biomol Inc. A fresh 10 mM stock solution of 2,7dichlorofluoroscein diacetate (DCFH-DA) was prepared in ethanol. Fresh D609
(1mg/ml) was prepared in phosphate-buffered saline (PBS). The cells were
preincubated with D609 for 1h before Aβ(1–42) was added. In some experiments, fresh
media were added after 1h preincubation of neuronal cells withD609. The protection
afforded by D609 was the same whether the xanthate was present for1h only of or the
entire 24 h period of Aβ(1–42) exposure. Assays for cell viability and protein oxidation
were performed 24 h after Aβ(1–42) treatment as previously described.
4.2.2 Synthesis of Methylated D609 (MD609)
MD609 was synthesized according to Barany et al. [31]. In brief, D609 (0.19 mg, 71
mM was dissolved in tetrahydrofuran(THF) (15 ml) and reacted with methyl iodide (0.5
ml, 8.0 mM) under nitrogen at 8 °C for 2 h. After 2 h the reaction was warmed to room
temperature and stirred for another 2 h to complete the reaction. The reaction was
quenched by water (20 ml) followed by extraction of the methylated product with ethyl
acetate (3 x 20 ml). The ethyl acetate was removed in vacuo, and the remaining yellow
liquid (16mg, 65mM) was verified as MD609 using 1H NMR.
4.2.3 Cell Culture
Cell cultures were grown by Dr. Hafiz Mohammad Abdul. Cortical neuronal
cultures were obtained from 18-day-old Sprague–Dawley rat fetuses. Aβ (1–42) peptide

36

was dissolved in sterile phosphate-buffered saline (PBS), pH 7.5, and pre-incubated for
24 h at 37 °C prior addition to cultures. The final concentration of the Aβ (1–42) peptide
in the cell culture was 10 µM, and its effects on the neuronal culture were measured after
24 h of exposure. The cells in the culture dishes were washed twice with PBS (pH 7.5)
and scraped in media-1buffer (0.32 M sucrose, 4 µg/ml leupeptin, 4 µg/ml pepstatin, 5
µg/ml aprotinin, 20 µg/ml trypsin inhibitor, and 0.2 mM PMSF). The scrapped cells were
sonicated and stored at –80 °C for further use.
Neuronal viability was determined by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazoliumbromide] reduction assay. Briefly, 24 h after exposure of cells to
Aβ(1–42), MTT in PBS was added to each well with final concentration of 1.0 mg/ml,
and incubated for 1h. The dark blue formazan crystals formed in intact cells were
extracted with 200ml of dimethyl sulfoxide (DMSO), and absorbance at 595nm was
measured with a microplate reader (Bio-Tek). Results were expressed as the percent of
MTT reduction, assuming that the absorbance of control cells was 100%.
4.2.4 Protein Estimation
The amount of protein in the samples was measured by bicinchoninic acid (BCA)
method by Pierce (Rockford, IL). Bovine serum albumin (BSA) was used as the protein
standard. The BSA standard underwent a serial dilution from 2.0 mg/ml, that was used
to produce a standard curve. Each sample (5 µL) including the including the standards
were dissolved in 0.02 mM BCA Reagent (sodium carbonate, sodium bicarbonate,
bicinchoninic acid, sodium tartrate in sodium hydroxide). Then 4% cupric sulfate
(CuSO4) was added to each well. These samples were then incubated for 10 min at 37
°C. Following the incubation, the samples are placed in the spectrophotometric plate
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reader measuring the absorbance at 562 nm. A standard curve is produced by the known
protein concentrations of the standard and the measured absorbances. The least square
best fit equation from that line was then used to determine the protein concentration of
the samples.

4.2.5 Protein Carbonyls
Protein carbonyls are an index of protein oxidation. The cell extract (5 mg of
protein) were derivatized with10 mM 2,4-dinitrophenylhydrazine in the presence of 5 ml
of 12% SDS for 20 min at room temperature. The samples were neutralized with 7.5 µL
of the neutralization solution (2M Tris in 30% glycerol). Derivatized protein samples
were blotted onto nitrocellulose membrane with a slot-blot apparatus (250 ng/lane).
Then the membrane was rinsed with wash buffer [10 mM Tris–HCl (pH 7.5), 150 mM
NaCl, 0.05% Tween 20]. The membane is then blocked by incubation in the presence of
5% BSA wash buffer (blocking buffer) overnight at 20 °C. This is followed by
incubation with rabbit polyclonal anti-DNPH antibody (200 µL in wash buffer) as the
primary antibody for 1.5 h. The membranes were washed with wash buffer 3 times for 5
min with fresh wash buffer. The blot was further incubated with alkaline phosphatase
(ALP)-conjugated goat anti-rabbit antibody as secondary antibody for 1 h. Blots were
developed using Sigma fast tablet (BCIP/NBT) in 10 mL of water. These blots were
then rinsed with water and dried. These dried blots were scanned and quantified using
Scion Image (PC version of Macintosh compatible NIH Image) software.
4.2.6 Statistical Analysis
The analysis of variance (ANOVA) was used to assess statistical significance
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between the Aβ (1-42) – treated neurons and the Aβ (1-42) + D609 – treated neurons.
ANOVA also was used to determine the significance between the D609 – and the
MD609 – treated neurons. ANOVA was used instead of the Student’s t test because
more than two groups needed to be compared in order to determine significance. A pvalue of less than 0.05 was used to designate a significance difference between two
groups.

4.3 Results
4.3.1 Effect of D609 on Cell Toxicity Induced by Aβ (1–42)
Exposure of neuronal cultures to Aβ (1–42) (10 mM) for 24 h reduced cell viability by
60% (p < 0.005) as seen in Figure 1. Pretreatment of neurons with D609 for 1 h
significantly attenuated Aβ (1–42)-induced cytotoxicity (p < 0.002). D609 attenuated
Aβ (1–42)-induced cell loss in a dose-dependent manner with maximal effects observed
at 50 mM. Thus, this concentration was used in the subsequent experiments. By itself,
D609 had no effect on cell viability. When neurons were treated with the MD609 no
significant protection against Aβ (1–42)-induced neurotoxicity was observed.
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Figure 4.1

D609 Prevents Aβ (1-42)-induced Cell Death

Figure 4.1 Effect of varying concentrations of D609 on cell viability induced by Aβ (1–
42) in primary cultured rat cortico-hippocampal neurons. D609 was added to the culture
1 h prior to10 mM Aβ (1–42) addition and the cells were incubated for 24 h. Cell
viability was assessed using MTT reduction. The data are the mean ± SEM expressed as
percentage of control values. Statistical comparison was made using ANOVA. (n = 5).
(*) < 0.005, Aβ (1–42) vs. Control; (**) < 0.002, Aβ (1–42) vs. Aβ (1–42) + D609, (***)
< 0.05.
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4.3.2 D609 Attenuated Aβ (1-42)-induced Protein Carbonyls
The ability of D609 to prevent protein oxidation was determined measuring protein
carbonyls. The level of protein carbonyls was compared between control, Aβ (1–42) –,
D609 plus Aβ (1–42) –, and MD609 plus Aβ (1–42) – treated neuronal cells. The level of
carbonyls was found to be significantly higher (p < 0.005) in Aβ (1–42)-treated cells
versus control cells, consistent with previous studies.[4,37] D609 treatment prior to
addition of Aβ (1–42) significantly reduced the level of carbonyl formation (p < 0.002).
However, MD609 did not protect neurons from Aβ (1–42)-induced protein oxidation
(Fig.4.2).
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Figure 4.2

Protective Effect of D609 Against Aβ (1-42)-induced Oxidation

Fig 4.2. Protective effect of 50m MD609 on Aβ (1–42)-induced protein oxidation
(protein carbonyl). Protein carbonyl content was determined as described in the section
4.2.5. The treatment of cell culture is the same as described in legend of Fig. 4.1. The
data are the mean ± SEM expressed as percentage of control values. Statistical
comparison was made using ANOVA. (n = 5). (*) < 0.005, Aβ (1–42) vs. Control,
MD609 vs. Control (**) < 0.002, Aβ (1–42) vs. Aβ (1–42) ± D609.

42

4.4 Discussion
Increasing evidence demonstrates that oxidative stress is an important contributor
in the pathogenesis of a number of neurodegenerative disorders that involve neuronal
degeneration and loss including AD [10]. Oxidative stress is caused mainly by an
imbalance in antioxidant and oxidant system. A shift towards oxidant levels cause a
wide spectrum of cell damage, including protein oxidation, lipid peroxidation and DNA
damage [8,6,39–43].
One of the important non-protein thiols involved in cellular defense against
oxidative stress is GSH. In cells, total GSH can be free or bound to proteins. Free GSH
is present mainly in its reduced form, which is converted to the oxidized form during
oxidative stress, and can be reverted to the reduced form by the action of the enzyme
GSH reductase [44,45]. The redox status of neurons depends on the relative amounts of
the reduced and oxidized forms of GSH (GSH/GSSG) and appears to be a critical
determinant of cell viability.
GSH functions in the detoxification of hydrogen peroxide, other peroxides and free
radicals [46]. A decrease of GSH concentration may be associated with aging and the
pathogenesis of many diseases, including AIDS, AD, amyotrophic lateral sclerosis.
Elevation of GSH may be a promising therapeutic strategy in AD [47]. GSH levels may
be altered due to altered enzyme levels involved in GSH metabolism [48,49]. Consistent
with the suggestion, Guet al. [50] provided evidence of altered GSH levels in specific
regions of CNS of subjects affected by AD. GSH has been shown to be protective
against various oxidative stressors found in AD. One of the substrates for GSH is HNE
[9,51] that was found to be increased in AD brain [52–55]. In addition, GSH can protect
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against peroxynitrite damage [19,20,56].
Previously, replenishment of GSH has been achieved with GSH monoesters and
diesters and with NAC or α-mercaptopropionylglycine [57,19–22]. Further, synthesis of
GSH from these precursors requires the active enzymes involved in GSH biosynthesis,
and when γ-glutamylcysteine ethyl ester (GCEE) is administered there is a chance of
forming 5-oxo-L-proline and L-cysteine by the action of γ-glutamylcyclotransferase on
L-γ-glutamyl-L-cysteine. D609 has been reported to protect against glutamate toxicity
and ionizing radiation-induced oxidative stress in lymphocytes by increasing the
intracellular levels of GSH. D609 has been reported to scavenge hydroxyl radical and
hydrogen peroxide [23].
The antioxidant property of D609 is associated with the free thiol group of xanthate
[23]. Consistent with this previous observation, here we show that methylation of the free
thiol of D609 ameliorated the antioxidant activity as indexed by protein carbonyl
production. Previous studies from our laboratory demonstrated the GSH mimetic
function of D609 as evidenced by formation of the dixanthate that is converted back to
the xanthate by GSH reductase analogous to the case with GSH. As shown in the current
study, protection of neuronal cells against Aβ (1–42) – induced oxidative stress and
neurotoxicity with D609, but not with MD609, suggests that the thiol group of D609
plays an important neuroprotective role against Aβ (1–42). This suggestion is consistent
with a protective mechanism of D609 being related to the GSH-mimetic properties of
this xanthate [23].
The results presented here demonstrated that Aβ (1–42) induces 60% reduction in
neuronal viability as assessed by the MTT assay (Fig. 4.1). This finding is consistent
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with the previous data from our laboratory and others [3,30,37,58]. In addition,
pretreatment of neuronal cells with D609 effectively protected neurons against Aβ (1–
42) – induced oxidative stress as indexed by decreased protein oxidation. The oxidation
of proteins by free radicals may be responsible for damaging enzymes critical in neuronal
function [59]. Protein carbonyl levels were found to be elevated in AD brains [6–8,34].
Previous studies from our laboratory identified oxidatively modified protein in AD brain
by proteomics analysis [41–43,59]. Neurons undergo apoptosis in response to oxidative
stress, an effect that is enhanced after GSH depletion data [67]. Here we showed that
treatment of neuronal cells with D609 protected neurons against Aβ (1–42) – induced
apoptosis.
That the same degree of neuroprotection was afforded byD609 whether the
xanthate was pre-incubated for 1 h with neurons followed by changing with fresh media
or by incubation with neurons for the full 24 h of exposure to Aβ (1–42) is consistent
with the notion that this xanthate provides neuroprotection by acting as a GSH mimetic
and not by direct inhibition of aggregation of Aβ (1–42).
The xanthate, D609 is a specific inhibitor of PC-PLC. Thus, while our findings that
D609, but not MD609, is protective against the oxidative stress and neurotoxicity
associated with Aβ (1–42), are consistent with the GSH – mimetic properties of this
xanthate as a principal mechanism of neuroprotection, we cannot completely rule out a
role of inhibition of PC-PLC by D609 in these findings. Similarly, since Aβ disrupts
Ca2+ homeostasis in neurons [68] and the action of PC-PLC may lead to altered Ca2+
dynamics, D609 potentially could be protective against oxidative stress in neurons in part
by modulating the resulting Ca2+ dyshomeostasis.
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In conclusion, this study has demonstrated that D609 protects neuronal cells from
oxidative stress induced by Aβ(1–42), known to be important in the pathogenesis of AD.
Neuronal cells pretreated with D609 displayed significant protection against Aβ (1–42)induced protein oxidation. Based on the data from the present and previous studies [23],
the thiocarboxylic acid group present in D609 may be responsible for its potential
antioxidant properties rather than drug-mediated inhibition of Aβ (1-42) aggregation.
Thus, the antioxidant properties of D609 conceivably could be beneficial in the treatment
of diseases related to oxidative stress, including AD.

Copyright © Shelley Faye Newman 2008
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CHAPTER FIVE
Protective effect of D609 against Aβ(1-42)-induced oxidative modification of
neuronal proteins: A redox proteomics study*.
5.1 Introduction
5.1.1 Redox Proteomics in Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disorder associated with the cognitive
decline and elevated oxidative stress (Butterfield and Lauderback 2002). The oxidative
stress has been directly linked to Amyloid-β peptide [Aβ (1-42)], the major protein
component of senile plaques, a pathological hallmark of AD (Markesbery 1997;
Butterfield et al. 2001; Selkoe 2001; Butterfield et al. 2002; Butterfield and Lauderback
2002). Aβ (1-42) is produced from the β- and γ-secretase cleavage of the transmembrane
glycoprotein, amyloid precursor protein (APP). Aβ (1-42) has been shown to induce
protein oxidation both in vitro and in vivo (Yatin et al. 1999; Drake et al. 2003;
Mohmmad Abdul et al. 2004). Further, studies using redox proteomics have linked the
in vitro treatment in primary neuronal culture of Aβ (1-42) to AD brain by the
identification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 14-3-3 zeta,
both which have been shown to be oxidized or dysfunctional in the AD brain (Layfield et
al. 1996; Cummings et al. 2005).
Protein oxidation is indexed using protein carbonyls or 3-nitrotyrosine. Protein
carbonyls are an oxidative damage marker of the formation of aldehydes on the protein
backbone and sidechains (Butterfield and Stadtman 1997). Redox proteomics utilizes a
two-dimensional separation of the proteins and a parallel identification of protein
*

This research was carried out in collaboration with Dr. Rukhsana Sultana and Dr. Jian
Cai
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expression and immunodetection of protein carbonyls (Butterfield et al., 2003; DalleDonne et al., 2006). This technique is then used to compare the oxidative damage
between the control and the oxidized control. However, more recently this technique has
also been used to determine which proteins are oxidized with the treatment of Aβ (1-42),
but whose oxidation can be prevented with the pretreatment of tricyclodecan-9-ylxanthogenate (D609).
5.1.2 D609
As discussed in chapter four, D609 is a known inhibitor of phosphatidylcholinespecific phospholipase C (PC-PLC). D609 has also previously been shown to have
antioxidant capabilities when given in vitro and in vivo (Sultana et al. 2004; Joshi et al.
2005). These antioxidant characteristics are thought to be linked to the xanthate
functionality in the compound, which allows it to form disulfide bonds between two
molecules when oxidized (Lauderback et al., 2003). This antioxidant mechanism is
similar to the mechanism of glutathione (GSH). GSH is the most abundant thiol in the
cell and the major antioxidant in the brain.

When oxidized, GSH forms a disulfide bond

between two GSH molecules to form GSSG, whose reduction is then catalyzed by
glutathione reductase (Lauderback et al. 2003).
Previous studies showed that the pretreatment of D609 prior to oxidation induced
by Aβ (1-42) in primary neurons reduced the level of protein carbonyls (Sultana et al.
2004). This protection was not seen when the thiol was blocked by methylation, further
proving that D609 uses the sulfur functionality to reduce oxidative damage products.
Though the overall reduction in protein carbonyls was known, it was unknown which
proteins were specifically protected by the pretreatment of D609. Two-dimensional
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proteomics was utilized to identify the proteins specifically oxidized by Aβ (1-42) and
protected by D609.
5.2 Experimental Procedures
5.2.1 Cell Culture Experiments
The cell culture samples were the same as prepared in section 4.2.3 of this
dissertation.
5.2.2 Sample Preparation
The samples were homogenized in a 10mM HEPES buffer (pH 7.4) containing
137 mM NaCl, 4.6 mM KCl, 1.1 mM KH2PO4, 0.6 mM MgSO4, and protease inhibitors
leupeptin (0.5 µg/ml), pepstatin (0.7 µg/ml), type II S soybean trypsin inhibitor (0.5
µg/ml), and PMSF (40 µg/ml). The protein concentration was estimated using the Pierce
BCA method as detailed in section 4.2.4.
5.2.3 Two – Dimensional Electrophoresis
From each sample 150 µg of protein was aliquoted and incubated at room
temperature for 30 min in four volumes of 10 mM 2,4-dinitrophenyl hydrazine and 2 M
HCl for protein carbonyl derivatization used in oxyblots for 2 M HCl for gel maps and
mass spectrometry analysis (Levine et al. 1994). Proteins were then precipitated with
addition of cold 100% trichloroacetic acid (TCA) with a final concentration of 15%. The
samples were then centrifuged at 14,000 × g and 4°C for 2 min. The pellet was then
washed three times with 500 µl of 1:1 (v/v) ethyl acetate/ethanol. The final pellet was
dissolved in rehydration buffer containing 8 M urea, 2 M thiourea, 2% CHAPS, 0.2%
(v/v) biolytes, 50 mM dithiothreitol (DTT), and bromophenol blue. The samples were
sonicated three times for 20 s on ice and then applied to the IPG Readystrip (pH 3-10)
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from Bio-Rad (Hercules, CA). Proteins were loaded onto the strip via active rehydration
was carried out for 16 h at 50 V and 20°C using the protean IEF cell (Bio-Rad).
Isoelectric focusing was then carried out at 20°C as follows: 800 V for 2 h linear
gradient, 1200 V for 4 h of slow gradient, 8000 V for 8 h of linear gradient, 8000 V for
10 h of rapid gradient. The strips were stored at -80 °C until second dimension was
performed. Gel strips were equilibrated before second dimension for 10 min in 50 mM
Tris-HCl (pH 6.8) containing 6 M urea, 1% (m/v) SDS, 30% (v/v) glycerol, and 0.5%
DTT followed by re-equilibrium for 10 min in the same buffer containing 4.5%
iodoacetimide in place of DTT. The gel strips were then placed in the linear gradient
precast Criterion Tris-HCl gels (8-16%, Bio-Rad) to perform the second dimension
electrophoresis. Precision protein standards (Bio-Rad) were run along the sample at 200
V for 65 min.
The gels were fixed in a solution containing 10% (v/v) methanol and 7% (v/v)
acetic acid for 20 min and then stained overnight at room temperature with agitation in
50 ml SYPRO Ruby gel stain (Bio-Rad).

5.2.4 Two – Dimensional Western Blotting
For immunoblotting analysis of DNPH derivatized samples, electrophoresis was
carried out as previously stated. The gels were transferred to a nitrocellulose membrane
using the Transblot-BlotSD Semi-Dry Transfer Cell at 45 mA per gel for 2 h. The
membranes were blocked with 2% bovine serum albumin (BSA) in PBS containing
0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBST) overnight at 4°C. The
membranes were incubated with polyclonal anti-2,4-dinitrophenylhydrazone (DNP)
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antibody (1:100) in PBST for 2 h with gentle rocking at room temperature. The
membranes were then washed three times for 5 min with PBST followed by incubation
with anti-rabbit alkaline phosphatase secondary antibody (1:3000) in PBST for 2 h at
room temperature. The membranes were then washed three times for 5 min with PBST
and then developed with SigmaFast tablets [5-bromo-4-chloro-3-indolyl phosphate/nitro
blue tetrazolium (BCIP/NBT)]. Blots were dried and scanned with Adobe Photoshop.

5.2.5 Image Analysis
The gels and nitrocellulose membranes were scanned by Scanjet 3300C Hewlett Packard,
Palo Alto, CA) and UV transilluminator (λex= 470nm, λem= 618nm) (Molecular
Dynamics, Sunnyvale, CA) respectively and saved in a TIFF format. PD Quest software
(Bio-Rad) was then used to compare the protein expression by 2D-gels and
immunoreactivity by 2D-blots. Average mode of background subtraction was used to
normalize intensity value, which represents the amount of protein (total protein on gel
and oxidized protein on oxyblot) per spot. After spots had been matched, the dataset was
obtained from the normalized intensity of each protein spot from the control, Aβ (1-42),
and D609 + Aβ (1-42) gels and oxyblots. In order to allow for protein concentration
changes the spot intensity values obtained on the blots are divided by the spot intensity
value on the gels to get the level of specific protein carbonyls. These, in turn, are
analyzed for significance using Student’s t-test.
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5.2.6 In-Gel Trypsin Digestion
Samples were prepared according to (Thongboonkerd et al. 2002). Based on the data
obtained from image analysis, the protein spots that showed a significant increase in
oxidation due Aβ (1-42) and protection by D609 were excised from gel with a clean
razor blade and transferred into a clean 1.5 ml microcentrifuge tubes. The gel pieces were
washed with 0.1M ammonium bicarbonate (NH4HCO3) for 15 min at room temperature
under a flow hood, followed by addition of acetonitrile and incubation at room
temperature for 15 min. The solvents were removed and the gel pieces were allowed to
dry. The gel pieces were incubated with 20 µl of 20 mM DTT in 0.1 M NH4HCO3 and
incubated for 45 min at 56°C. The DTT solution was removed and 20 µl of 55 mM
iodoacetamide (IA) in 0.1 M NH4HCO3 was added and incubated for 30 min in the dark
at room temperature. The liquid was removed and the gel pieces were incubated with 200
µl of 50 mM NH4HCO3 at room temperature for 15 min. Acetonitrile was then added to
the gel pieces for 15 min at room temperature. The solvents were removed and the gel
pieces were allowed to dry for 30 min. The gel pieces were rehydrated with 20 ng/µl
modified trypsin (Promega, Madison, WI) in 50 mM NH4HCO3. The gel pieces were cut
into small pieces and incubated while shaking overnight (~18 h) at 37°C.
5.2.7 Mass Spectrometry
The mass spectra of the sample were determined by a Tof-Spec 2E (Micromass, UK)
MALDI-TOF mass spectrometer operated in reflectron mode. One microliter of trypsindigested protein was mixed with 1 µl α-cyano-4-hydroxy-trans-cinnamic acid (10 mg/ml
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in 0.1% TFA:ACN, 1:1, v/v) directly on the target and allowed to dry at room
temperature. The sample spot was then washed with 1µl of 1% TFA solution for
approximately 60 s. The TFA droplet was gently blown off the sample spot with
compressed air. The resulting diffuse sample spot was recrystallized (refocused) using 1
µl of a solution of ethanol:acetone:0.1% TFA (6:3:1). Reported spectra are a summation
of 100 laser shots. External calibration of the mass axis, used for acquisition
and internal calibration using either trypsin autolysis ions or matrix clusters were applied
post acquisition for accurate mass determination.
5.2.8 Peptide Sequence Analysis
The MALDI spectra from the tryptic fragments used for protein identification were
searched against the entire NCBI and SwisProt protein databases using the MASCOT
search engine (http://www.matrixscience.com). Peptide mass fingerprinting uses the
assumptions that peptides are monoisotopic, oxidized at methionine residues, and
carbamidomethylated at cysteine residues and also allows for up to one missed trypsin
cleavage. Mass tolerance of 150 ppm was the window of error allowed for matching the
peptide mass values. Probability-based MOWSE scores were estimated by the
comparison of search results against estimated random match population and were
reported as 10*log10(p), where p is the probability that the identification of the protein
is not correct. MOWSE scores greater than 59 were considered to be significant (p <
0.05). Protein identifications were determined to be in the expected size and pI range
based on position in the gel. Previous proteomics analysis of AD brain proteins from our
laboratory were verified in some cases by immunochemical methods. Thus, we are
confident in the correct identity of the proteins that were identified in this paper.

53

5.2.9 Statistical Analysis
The comparison of protein levels and protein specific carbonyl levels were analyzed by
two-tailed Student’s t-tests, as generally used for proteomics analysis. A value of p <0.05
was considered statistically significant. A similar statistical analysis is usually used for
proteomics data analysis. Only the statistically significant comparisons between the
untreated control and Aβ (1-42)-treated neurons as well as between the D609 followed
by Aβ (1-42)-treated neurons and only Aβ (1-42)-treated neurons were subjected to
proteomics analysis.
5.3 Results
5.3.1 D609 Protects Specific Proteins Oxidized by Aβ (1-42)
Comparison of untreated control and Aβ (1-42) treated neuronal protein oxidation
levels was carried out by first identifying carbonylated proteins via anti-DNP
immunochemical detection of proteins transferred to a nitrocellulose membrane, or 2Doxyblot analysis (Figure 5.1), followed by comparison of 2D blots with 2D gels.
Individual protein spots were matched between the 2D-PAGE maps and the 2D-oxyblots
and the carbonyl immunoreactivity of each spot was normalized to the protein content in
the 2D-PAGE (Figure 5.1). A comparison of protein oxidation of neurons treated with
Aβ (1-42) or D609 pretreatment followed by Aβ (1-42) addition was carried out in the
same means. The number of proteins visualized in the 2D-PAGE is larger than the
proteins in the 2D-oxyblot, which is confirmed from previous studies stating that not all
proteins are carbonylated.
The comparisons using PD Quest led to the identification of 4 spots found to be
significantly more carbonylated in the Aβ (1-42)-treated neurons when compared to the
untreated neurons. These same spots were then found to have a significant decrease in
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carbonylation if the neuronal cultures were first treated with D609 prior to the Aβ (1-42)
addition. With the use of mass spectrometry and database searching these proteins were
identified. Pyruvate kinase (1440 ± 100%, P < 0.01), malate dehydrogenase (450 ± 40%,
P < 0.03), GAPDH (980 ± 105%, P < 0.02), and 14-3-3 zeta (240 ± 80%, P < 0.03) were
all identified as significantly more carbonylated with the addition of Aβ (1-42). The
numbers in parenthesis represent a specific oxidation of each representative protein and
was obtained by dividing the intensity of the particular spot on the 2D Western blot by
the intensity of the same representative spot on the 2D gel. This oxidation was then
reduced with the pretreatment of D609 (Figure 5.1). The MASCOT database identified
pyruvate kinase with a MOWSE score of 84, matching 10 of 26 peptides and a 23%
sequence coverage. Malate dehydrogenase’s MOWSE score was 110 with a 12 of 25
peptides matched and a 30% sequence coverage, while GAPDH had a MOWSE score of
88 with 16 of 34 peptides matched and a 25% sequence coverage. The final protein 143-3 zeta had a MOWSE score of 76, 7 of 18 peptides matched, and a 35% sequence
coverage. These findings are summarized in Table 5.1.
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Figure 5.1
2D Blots and Gels

Figure 5.1: SYPRO Ruby-stained gels and 2D-oxyblots are present from top to bottom:
control neurons, neurons treated with Aβ (1-42), neurons pretreated with D609
followed by Aβ (1-42). The boxes label the proteins identified in this study.
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Table 5.1
Summary of Proteins Identified as Significantly Oxidized According to Protein
Carbonyl level in Neurons Treated with Aβ (1-42)1
Oxidatively Modified
Proteins

# Peptides matched
in the identified
protein

Percent coverage of
the matched peptides

pI, Mr (kDa)

MOWSE Score

Protein Oxidation

2 P Values

GAPDH

16/34

25%

7.66, 31.29

88

980 ±105

< 0.02

14-3-3 Zeta

7/18

35%

4.55, 29.27

76

240 ± 80

< 0.03

Pyruvate Kinase

10/26

23%

7.59, 58.40

84

1440 ± 100

< 0.01

Malate
Dehydrogenase

12/25

30%

6.6, 36.01

110

450 ± 40

< 0.03

1

For each protein the carbonyl immunoreactivity / protein expression values were
averaged (n = 6) and are presented as percentage control ± SEM. GAPDH,
glyceraldehyde-3-phosphate; Mr, relative mobility.
2
Protein oxidation was obtained by dividing the intensity of the respective spot on the
2D Western blot by the intensity of the corresponding 2D gel spot.
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5.4 Discussion
The oxidative damage found in AD is extensive with a significant increase in
protein oxidation, lipid peroxidation, and DNA oxidation. Protein oxidation parameters
such as: protein carbonyls, 3-nitrotryosine modified proteins, and hydroxynonenal
modified proteins have been measured in human AD brain (Butterfield 2004). These
parameters have also been shown to be elevated with the in vitro treatment of Aβ (1-42)
in cell culture (Boyd-Kimball et al. 2005a) as well as the injection of Aβ (1-42) into
brain in vivo (Boyd-Kimball et al. 2005b). With the use of redox proteomics the specific
proteins oxidized by Aβ (1-42) have also been identified. The redox proteomics
approach can then be used to identify the protection of these proteins by antioxidant
treatments. Proteomics can give insight into the mechanism of protection along with the
identification of an overall reduction in oxidative damage.
The protection of neurons can be facilitated using an antioxidant. GSH is one of
the most important antioxidants in the brain, which has been measured in millimolar
concentrations. This concentration has been shown to decline with age consequently
leaving neurons vulnerable to oxidative insult (Liu and Choi 2000). This depletion in
GSH can be augmented with a GSH mimetic, in principle, to combat the oxidative
damage seen in AD brains. D609, a GSH mimetic, has been shown to reduce oxidative
stress in both in vitro and in vivo systems (Sultana et al. 2004; Joshi et al. 2005). D609 is
a xanthate molecule that has a sulfur functionality that allows it to form disulfide bonds
when oxidized. The disulfide bonds can then be reduced using GSH reductase as shown
in previous work (Lauderback et al. 2003). As a potential AD therapeutic it was

58

imperative to understand the individual proteins that were being protected by the
treatment of D609 against the oxidation of Aβ (1-42).
Using proteomics tools malate dehydrogenase, pyruvate kinase, GAPDH, and 143-3 zeta were identified in neurons as significantly more carbonylated by the treatment of
Aβ (1-42) and protected by the pretreatment of D609. Previous studies have linked
protein oxidation to enzyme dysfunction (Hensley et al. 1995; Subramaniam et al. 1997;
Yatin et al. 1999; Aksenov et al. 2000). Using this precedent, plausible
neurodegenerative mechanisms can be derived from the dysfunction of the proteins
identified as well as benefits of their protection.
Pyruvate kinase, GAPDH, and malate dehydrogenase are all glycolytic enzymes
involved in the production of ATP. These enzymes have been shown to be oxidatively
modified in other aging or AD related models (Boyd-Kimball et al. 2005a; Lovell et al.
2005; Poon et al. 2005). Pyruvate kinase catalyzes the final step in glycolysis forming
ATP from ADP when converting phosphoenolpyruvate to pyruvate. This enzyme
controls the flow of glucose into synthetic pathways or into metabolism, so it is crucial to
the energy regulation of the cell. A decrease in ATP production would accordingly alter
cell potential and lead to dysfunction in electrochemical gradients, ion pumps, and
voltage-gated ion channels, among other detrimental effects. These are components of a
delicately balanced system used to defend against oxidative stress of synaptic regions of
neurons induced by Aβ(1– 42). Previous publications from our laboratory sustain this
hypothesis identifying α-enolase, triosephosphate isomerase, and creatine kinase as
oxidatively modified in AD brain (Castegna et al. 2002b; Castegna et al. 2002a; Castegna
et al. 2003; Sultana et al. 2006c; Sultana et al. 2006a; Sultana et al. 2006b). Malate
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dyhydrogenase is also essential to energy production and regulation. This enzyme
catalyzes the conversion from malate to oxaloacetate in glycolysis also producing an
ATP from ADP. The production of ATP ensures the maximum glutamate accumulation
into presynaptic vesicles. Malate dehydrogenase is located within the mitochondrial
matrix in order to connect glycolysis to mitochondrial respiration. The activity of this
enzyme is also decreased during aging, which could be related to oxidative modification
(Stadtman et al. 1993). The oxidation of the protein, potentially resulting in enzyme
dysfunction could result in alterations in ATP availability, synaptic plasticity, and
neuronal recovery due to its relationship with glutamate regulation. In addition, given its
location, mitochondrial alterations conceivably could result as well.
GAPDH is also a glycolytic enzyme that has been previously identified as
oxidized by Aβ (1-42) in neurons (Boyd-Kimball et al. 2005b). GAPDH is located in the
cytosol where it catalyzes the conversion of glyceraldehyde-3-phosphate to 1,3phosphoglycerate. This is the first oxidation-reduction reaction in the glycolytic
pathway. GAPDH as well as other glycolytic enzymes such as α-enolase and γ-enolase
has also been shown to accumulate in AD brain (Schonberger et al. 2001). Oxidation of
GAPDH potentially leading to the loss of enzyme function could result in decreased ATP
production. This is consistent with the altered glucose tolerance and metabolism
confirmed by positron emission tomography (PET) scanning studies of AD patients
(Blass and Gibson 1991; Vanhanen and Soininen 1998; Messier and Gagnon 2000;
Scheltens and Korf 2000).
GAPDH has been connected with two of the major components of AD. Oxidized
GAPDH was previously isolated from neurofibrillary tangles in the AD hippocampus
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(Sultana et al. 2006b; Wang et al. 2005). Studies have also shown that GAPDH is bound
to the C-terminal end of APP and Aβ (1-42) (Oyama et al. 2000; Schulze et al. 1993).
The effect of this binding is not completely known though potentially this binding
regulates the clearance of Aβ peptide (Oyama et al. 2000). This could also directly
explain the oxidation of GAPDH in the AD brain, since AD is known to induce oxidative
stress (Butterfield et al. 2007).
The protein, 14-3-3 zeta was also previously identified as oxidized in neurons
treated with Aβ (1-42) (Boyd-Kimball et al. 2005a). This protein is a cytosolic protein
that is found primarily in the gray matter in rats (Takahashi 2003). 14-3-3 zeta is an
isoform of an ubiquitous and highly conserved 14-3-3 protein family. This protein
family is expressed abundantly in the brain and constitutes approximately 1% of total
soluble brain protein (Takahashi 2003; Dougherty and Morrison 2004). 14-3-3 proteins
play a role in a variety of cellular functions including signal transduction, metabolism,
cell cycle regulation, protein trafficking, apoptosis, and stress responses by binding
specific target proteins (Dougherty and Morrison 2004). By binding to a target protein,
14-3-3 can regulate the target protein in a variety of ways including acting as a bridge
(adaptor/scaffold) between two target proteins, increasing or inhibiting the intrinsic
catalytic activity of the target protein, and protecting the target protein from proteolysis
and dephosphorylation (Takahashi 2003).
Previous studies have revealed that the levels of 14-3-3 proteins are increased in
AD brain (Fountoulakis et al. 1999) and are associated with neurofibrillary tangles (NFT)
in AD brain (Layfield et al. 1996). NFTs are another pathologic hallmark of AD and are
composed of paired helical filaments containing hyperphosphorylated tau. Tau is a
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microtubule-associated protein that becomes hyperphosphorylated and dissociates from
microtubules resulting in microtubule instability and neurodegeneration. This disruption
of microtubules has pronounced consequences on retrograde and antergrade axonal 14-33 zeta has been shown to act as an effector of tau protein phosphorylation (Hashiguchi et
al. 2000) and may act as a scaffolding protein to promote the polymerization of tau
protein by simultaneously binding to tau and glycogen synthase kinase 3β (GSK3β) in a
multiprotein tau phosphorylation complex (Hernandez et al. 2004); (Agarwal-Mawal et
al. 2003). GSKβ is one of the kinases involved in the hyperphosphorylation of tau
(Grimes and Jope 2001). It has been proposed that 14-3-3 binding may alter the
conformation of tau making it more susceptible to phosphorylation due to the different
regulatory mechanisms exerted by 14-3-3 on its target proteins (Hashiguchi et al. 2000).
Additionally, binding of 14-3-3 may protect the hyperphosphorylated form of tau from
dephosphorylation, therefore promoting the formation of NFTs (Agarwal-Mawal et al.
2003).
The proteins identified in this study confirm earlier studies of Aβ (1-42) oxidation
of GAPDH and 14-3-3 zeta, while also identifying two new proteins. Pyruvate kinase,
malate dehydrogenase, and GAPDH are all glycolytic enzymes, and dysfunction due to
oxidation could cause alterations in glucose metabolism as reported in the AD brain
(Vanhanen and Soininen 1998; Messier and Gagnon 2000; Scheltens and Korf 2000).
Other glycolytic enzymes such as α-enolase, triosephosphate isomerase, and creatine
kinase have been identified as oxidized in the AD brain (Castegna et al. 2002a; Castegna
et al. 2003). There have also been many reports of the alteration of 14-3-3 zeta and its
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association with tau in the AD brain (Layfield et al. 1996; Fountoulakis et al. 1999;
Hashiguchi et al. 2000).
This study also shows that D609 does not only reduce the overall oxidative
damage due to Aβ (1-42), but it can be seen that the proteins specifically oxidized by Aβ
(1-42) are protected. Future studies could investigate these specific proteins and how
their oxidation effects the neuron and the benefits of its protection by D609.

Copyright © Shelley Faye Newman 2008
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CHAPTER 6
An increase in S-glutathionylated proteins in the Alzheimer's disease inferior
parietal lobule, a proteomics approach
6.1 Introduction
6.1.1 Glutathione
In order to prevent oxidative damage, cells and tissues have antioxidant systems
to scavenge ROS and RNS. These antioxidant systems include a low molecular weight
thiol compound, glutathione (GSH), which is present at high concentrations (0.5–10
mM) in brain cells (Halliwell and Gutteridge 1999; Sies 1999). GSH is composed of
three amino acids (γ-glutamyl-cysteinyl-glycine), in which the thiol on the cysteine plays
an important role in maintaining the cellular redox state under oxidative stress. The
general mechanism of this protection comes from the ability of GSH to form a disulfide
(GSSG) when oxidized, which can then be reduced back to GSH by glutathione
reductase. This process makes GSH a recyclable antioxidant molecule.
6.1.2 S-Glutathionylation of Proteins
Previous research shows that moderate oxidation can result in the formation of a
mixed disulfide bond between protein cysteine side chains (PSH) and GSH to form Sglutathionylated proteins (PSSG) (Dalle-Donne et al. 2003). S-glutathionylation is a
reversible post-translational modification from which the release of GSH can be
catalyzed enzymatically by glutaredoxin, a thioltransferase (Chrestensen et al. 2000;
Cotgreave et al. 2002; Shenton et al. 2002). The cell could potentially utilize Sglutathionylation as a form of redox regulation of protein function and activity
(Casagrande et al. 2002; Dalle-Donne et al. 2003; Klatt and Lamas 2000).
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The purpose of the current study was to use redox proteomics to identify those
proteins that have increased S-glutathionylation in AD brain. These results provide
insight into how the proteins are important to pathology of AD and how are they maybe
related to other oxidative modifications.
6.2 Experimental Procedures
6.2.1 AD and Control Subjects
The samples used for this study were obtained from the inferior parietal lobule
(IPL) of five AD patients and five aged matched controls. The autopsy samples had
average postmortem intervals (PMIs) of 3.11 h for AD patients and 3.15 h for control
subjects provided by the Rapid Autopsy Program of the University of Kentucky
Alzheimer’s Disease Clinical Center (UK ADC) (Table 6.1). All AD patients displayed
progressive intellectual decline and met NINCDS-ADRDA Workgroup criteria for the
clinical diagnosis of probable AD (McKhann et al. 1984). Hematoxylin–eosin and
modified-Bielschowsky staining and 10-D-5, and α-synuclein immunohistochemistry
were used on multiple neocortical, hippocampal, entorhinal, amygdala, brainstem, and
cerebellum sections for diagnosis. Some patients were also diagnosed with AD plus
dementia with Lewy bodies. Control subjects underwent annual mental status testing and
semi-annual physical and neurological exams, as a part of the UK ADC normal volunteer
longitudinal aging study and did not have a history of dementia or other neurological
disorders. All control subjects had test scores in the normal range.. Neuropathologic
evaluation of control brains revealed only age-associated gross and histopathologic
alterations. Other characteristics of AD and control patients that were available from
medical records are provided in Table 1.
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Table 6.1
Demographic Data of AD and Control Subjects (Mean ± S.D.)
Samples
(n=5)
Control

Post-Mortem
Intervals (h)
3.15 ± 0.93

Age
(years)
83 ± 13

Sex
4F/1M

Brain Weight
(g)
1149 ± 151

AD

3.11 ± 0.46

85 ± 8

4F/1M

1056 ± 150

Abbreviations: AD, Alzheimer’s disease; S.D., Standard deviation; n, number of
individuals
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6.2.2 Sample Preparation
Brain samples were sonicated and suspended in 10mM HEPES buffer (pH 7.4)
containing 137mM NaCl, 4.6mM KCl, 1.1mM KH2PO4, 0.1mM EDTA, and 0.6mM
MgSO4 as well as proteinase inhibitors: leupeptin (0.5 mg/mL), pepstatin (0.7µg/mL),
type II S soybean trypsin inhibitor (0.5µg/mL), and PMSF (40 µg/mL). Homogenates
were centrifuged at 14,000×g for 10 min to remove debris. Protein concentration in the
supernatant was determined by the BCA method (Pierce, Rockford, IL, USA).
6.2.3 Two-dimensional Electrophoresis
From each sample 150 µg of protein were aliquoted and dissolved in rehydration
buffer containing 8 M urea, 2% CHAPS, 0.2% (v/v) biolytes, and bromophenol blue. The
samples were sonicated three times for 20 s on ice and then applied to the IPG
Readystrip (pH 3-10) from Bio-Rad (Hercules, CA). Proteins were loaded onto the strip
via active rehydration that was carried out for 16 h at 50 V and 20°C using the protean
IEF cell (Bio-Rad). Isoelectric focusing was then carried out at 20°C as follows: 800 V
for 2 h linear gradient, 1200 V for 4 h of slow gradient, 8000 V for 8 h of linear gradient,
8000 V for 10h of rapid gradient. The strips were stored at -80°C until second
dimensional separation was performed. Gel strips were equilibrated before second
dimension for 15 min in 50 mM Tris-HCl (pH 6.8) containing 6 M urea, 1% (m/v) SDS,
and 30% (v/v) glycerol. The gel strips were then placed in the linear gradient precast
Criterion Tris-HCl gels (8-16%, Bio-Rad) to perform the second dimension
electrophoresis. Precision protein standards (Bio-Rad) were run along the sample at 200
V for 65 min. The gels were fixed in a solution containing 10% (v/v) methanol and 7%
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(v/v) acetic acid for 20 min and then stained overnight at room temperature with agitation
in 50 ml SYPRO Ruby gel stain (Bio-Rad, Hercules, CA).
6.2.4 Two-Dimensional Western Blotting
For immunoblotting analysis, electrophoresis was carried out as stated in the
above section. The gels were transferred to a nitrocellulose membrane using the
Transblot-BlotSD Semi-Dry Transfer Cell at 45 mA per gel for 2 h. The membranes
were blocked with 2% bovine serum albumin (BSA) in PBS containing 0.01% (w/v)
sodium azide and 0.2% (v/v) Tween 20 (PBST) overnight at 4 °C. The membranes were
incubated with rabbit monocolonal anti-GSH (Virogen, Watertown, MA) (1:10) in PBST
for 2 h with gentle rocking at room temperature. The membranes were then washed three
times for 5 min with PBST followed by incubation with anti-rabbit alkaline phosphatase
secondary antibody (1:3000) in PBST for 2 h at room temperature. The membranes were
then washed three times for 5 min with PBST and developed with SigmaFast tablets [5bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT)]. Blots were
dried and scanned with Adobe Photoshop.
6.2.5 Image Analysis
The image analysis was completed as detailed in section 5.2.5 of this dissertation.
6.2.6 In-Gel Trypsin Digestion
The in-gel trypsin digestion was carried out with the same protocol as described
in section 5.2.6 of this dissertation.
6.2.7 Mass Spectrometry
The peptide mass fingerprint was determined using the same protocol as
described in section 5.2.7 of this dissertation.
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6.2.8 Protein Identification
Proteins were identified using the Mascot search engine as described in section
5.2.8 of this dissertation.
6.2.9 Enzyme Activity
The specific activities of GAPDH and α-enolase were determined using a
protocol outlined by the supplier [Sigma Aldrich (St. Louis, MO)]. The same age-match
control (n=5) and AD (n=5) samples were used in this analysis as were used in
proteomics study. Proteins were precipitated with the addition of cold 100%
trichloroacetic acid (TCA) for a final concentration of 15%. The samples were then
centrifuged at 14,000 × g and 4°C for 2 min. The resulting pellet was then washed with
500 µl of 1:1 (v/v) ethyl acetate/ethanol. Centrifugation and washing was repeated three
times to remove any remaining lipids. The protein sample was then dissolved in100 mM
triethylamine buffer (pH 7.4) for a final concentration of 0.750 µg/µl.
To determine the activity of GAPDH 5 µg of protein was added to an assay
mixture (100 mM 3-phosphoglyceric acid, 200 u/ml 3-phosphoglyceric phosphokinase,
200 mM cysteine, 100mM MgSO , 34mM ATP, 7.0mM β-NADH) in a UV-transparent
4

microtiter plate (Corning, MA). The change in absorbance at 340 nm was monitored
during a five minute period using a powerwave X plate reader (Bio-Tek Instrument Inc.
Winooshi, VT).
To analyze the activity of α-enolase 5 µg of protein sample was added to an assay
mixture (56 mM 2-phosphoglycerate, 20 mM ADP, 700 u/ml pyruvate kinase, 7 mM βNADH, 1000 u/ml L-lactic dehydrogenase) in a UV-transparent microtiter plate
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(Corning, MA). The decrease in absorbance 340 nm was recorded over five minutes
using a powerwave X plate reader (Bio-Tek Instrument Inc. Winooshi, VT
6.2.10 Statistical Analysis
The data concerning the enzymatic activities of GAPDH and α-enolase were
analyzed by Student’s t-test. The significance of the change in S-glutathionylation of
specific proteins in the proteomics study was evaluated using the non-parametric MannWhitney-Wilcoxon test. A p<0.05 was considered statistically significant.
6.3 Results
6.3.1 Identification of Specific S-Glutathionylated Proteins
To identify S-glutathionylated proteins, images of the blots and gels of the
samples were compared by the PD Quest software, and individual protein spots from the
2D blot were normalized to the amount of protein in the 2D gel (Fig. 6.1). This analysis
verified that not all of the protein spots with increased immunoreactivity show an
increase in S-glutathionylation, but the increase correlates to an increase in protein
expression in AD brain (Castegna et al. 2002a; Castegna et al. 2002b; Poon et al. 2004).
The 2D blot of AD IPL revealed four significantly increased S-glutathionylated protein
spots compared to those of age-matched control IPL (Fig. 6.1). The identified protein
spots were subjected to mass analysis using MALDI mass spectrometry for protein
identification after in-gel trypsin digestion. The Mascot search engine successfully
identified the four modified proteins. Table 6.2 shows the proteins identified with the
peptides matched, percentage coverage, and pI and Mr values. Hemoglobin β, αcrystallin B, GAPDH, and α-enolase were identified by quantitative redox proteomics to
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be S-glutathionylated in the AD IPL as compared to control brain. The percent increase
protein S-glutathionylation for the identified protein spots in AD are shown in Table 6.3.

6.3.2 Enzymatic Activity of GAPDH and α-enolase
In order to help validate the post-translational modification of proteins identified
in this research, activities of two enzymes identified were measured. The measurement
of enzymatic activity of GAPDH (Fig. 6.2) and enolase (Fig. 6.3) from AD IPL revealed
decreased activity compared to the age-matched control. A comparison between the
previously reported oxidized proteins in AD IPL (Castegna et al. 2002a; Castegna et al.
2002b) and the currently identified S-glutathionylated proteins in AD IPL revealed αenolase as oxidatively modified in both studies. GAPDH has not been previously
identified as oxidized in the IPL region of the AD brain; however, previous studies do
show that GAPDH is oxidized in the AD hippocampus (Sultana et al. 2006b).
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Figure 6.1

Figure 6.1: The proteins from AD and age-matched controls were separated using 2D
electrophoresis. The gels are then stained with SYPRO Ruby stain.
Representative control and AD gels are displayed at the bottom of the figure. 2Doxyblots, demonstrate the immunochemical detection of glutathionylated
proteins. Representative control and AD blots are presented at the top of the
figure. The protein spots are labeled with the proteins identified in this study.
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Figure 6.2

Figure 6.2: The measurement of GAPDH enzyme assay was performed as described in
the section 6.2.9 of this dissertation. The age-matched control and AD IPL
samples were the same as those used for redox proteomics. The data are the mean
± SEM expressed as units per ml. Statistical comparison was made using twotailed Student’s t-tests. (n=5). (*)<0.05, AD vs. Age-matched control
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Figure 6.3

Figure 6.3: The measurement of enolase enzyme assay was performed as described in the
section 6.2.9 of this dissertation. The age-matched control and AD IPL samples
were the same as those used for redox proteomics. The data are the mean ± SEM
expressed as units per ml. Statistical comparison was made using two-tailed
Student’s t-tests. (n=5). (*)<0.02, AD vs. Age-matched control
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Table 6.2
Summary of Glutathionylated Proteins in the AD IPL Identified with Mass
Spectrometry
Identification
α-enolase

# Peptides matched
of identified protein
15/23

% Coverage of
matched peptides
39

pI, Mr
(kDa)
7.01,47.5

Mowse
Score
182

GAPDH

8/25

36

8.57,36.1

89

Hemoglobin β

14/31

95

6.76,15.8

204

α-crystallin B

10/43

56

6.76,20.1

116

Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; pI, isoelectric
point; Mr, relative mobility
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Table 6.3
Summary of Identified S-glutathionylated Proteins in AD IPL
Protein

p value

α-enolase

Protein Oxidation
(% Control ± SEM)
549 ± 196

GAPDH

740 ± 260

0.027

Hemoglobin β

459 ± 94

0.047

α-crystallin B

435 ± 121

0.027

0.028

Abbreviations: GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; SEM,
standard deviation of the mean
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6.4 Discussion
The increase of oxidative stress in the AD brain results in an increase in oxidized
proteins. Oxidatively modified proteins generally demonstrate impaired protein function,
as observed in the previous and present studies, altering cell function and potentially
resulting in neuronal death (Butterfield 2004; Hensley et al. 1995; Lauderback et al.
2003). Specific proteins appear to be more prone to oxidation, so proteomics is used to
determine which proteins have an increase in oxidative modifications (Butterfield et al.
2003; Castegna et al. 2002a; Castegna et al. 2002b; Poon et al. 2006).
A number of proteins that have been identified by redox proteomics as oxidized
in the AD brain are involved in energy metabolism, mitochondrial function, cell cycle,
synaptic plasticity, excitotoxicity, proteosomal dysfunction, lipid abnormalities, neuritic
abnormalities, tau hyperphosphorylation, etc. (Butterfield and Boyd-Kimball 2004b;
Castegna et al. 2002a; Castegna et al. 2002b; Sultana et al. 2005a; Sultana et al. 2005b;
Sultana et al. 2006b; Butterfield et al. 2007). The loss of protein function due to
oxidative modification could be a plausible mechanism for neurodegeneration found in
the AD brain.
Glutathione is a natural antioxidant recycled by neurons to protect cell function
from oxidative stress (Klatt and Lamas 2000). During oxidative stress, GSH reacts with
oxidized cysteine residues of proteins as a transient modification, S-glutathionylation.
This could potentially serve as protection from irreversible, more dangerous oxidation of
cysteine residues (Baty et al. 2005; Souza and Radi 1998). A previous study of Sglutathionylated actin showed that there is a reduction in function, which can then be
reversed with GSH or DTT (Dalle-Donne et al. 2003). In the present study, we identified
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the specific targets of S-glutathionylation in AD inferior parietal lobule when compared
to age-matched controls. The identification of both α-enolase and GAPDH confirm
previous studies that these proteins contain oxidative modifications in the AD brain
(Sultana et al. 2005b; Sultana et al. 2006b). Hemoglobin β and α-crystallin B were also
identified as showing an increase in S-glutathionylation, though these proteins have not
been previously identified as oxidized in the AD brain. The role of S-glutathionylation
has not been completely elucidated, though some studies report S-glutathionylation as a
protective mechanism to divert from permanent protein oxidation while other studies
show the potential of S-glutathionylation as a redox regulation of protein function
reactions (Dalle-Donne et al. 2003; Thomas et al. 1995; Yang et al. 2002).
GAPDH has been connected with two of the major components of AD. Oxidized
GAPDH was previously isolated from neurofibrillary tangles in the AD hippocampus
(Sultana et al. 2006b; Wang et al. 2005). Studies have also shown that GAPDH is bound
to the C-terminal end of APP and Aβ (1-42) (Oyama et al. 2000; Schulze et al. 1993).
The effects of this binding is not completely known though potentially this binding
regulates the clearance of Aβ peptide (Oyama et al. 2000). This could also directly
explain the oxidation of GAPDH in the AD brain, since AD is known to induce oxidative
stress (Butterfield et al. 2007).
Reduced activity of GAPDH in the AD IPL (Figure 2) due to oxidation could
cause alterations in glucose metabolism, which has been reported in the AD brain
(Messier and Gagnon 2000; Scheltens and Korf 2000; Vanhanen and Soininen 1998).
GAPDH is a cytosolic protein that catalyzes the conversion of glyceraldehyde-3phosphate to 1,3-phosphoglycerate, which is the first oxidation-reduction reaction in the
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glycolytic pathway. The breakdown of glucose is the most prevalent mechanism by
which the brain produces ATP and consequently energy making the glycolytic pathway
crucial neuron survival. The oxidation and decrease in activity of GAPDH was
previously reported in the AD hippocampus and now in the IPL region is consistent with
the altered glucose tolerance and metabolism confirmed by positron emission
tomography (PET) scanning studies of AD patients (Blass and Gibson 1991; Messier and
Gagnon 2000; Scheltens and Korf 2000; Sultana et al. 2006a; Sultana et al. 2006b;
Vanhanen and Soininen 1998). This information combined with recent data suggests that
altered function of GAPDH due to oxidative conditions could lead to neuronal death
(Hara et al. 2006; Hernandez-Fonseca et al. 2005; Opii et al. 2006).
How S-glutathionylation alters the function of GAPDH is not clearly known, but
studies confirm that the modification reduces activity and is reversible with available
reduced GSH (Dalle-Donne et al. 2003; Mohr et al. 1999). Other studies show that Sglutathionylation does not specifically decrease the activity, but the oxidation of the
cysteine residue reduces GAPDH activity (Eaton et al. 2002; Lind et al. 1998). An
increase of GAPDH disulfide bonds in the AD brain, which can also be induced by the
introduction of proxidants in neuronal cells, has been shown in previous work. This study
supports the hypothesis that increased oxidative stress in the AD brain can increase Sglutathionylation of GAPDH (Cumming et al. 2004; Cumming and Schubert 2005).
Recent work shows GAPDH acts as a NO sensor showing drastic reduction activity when
nitrosylated, which is also confirmed in the AD brain (Castegna et al. 2003; Hara et al.
2006; Sultana et al. 2006c). This activity can also be recovered with the addition of GSH
(Batthyany et al. 2006). This knowledge leads to the hypothesis that GAPDH is sensitive
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to oxidation, and S-glutathionylation serves as temporary shield allowing GAPDH to
continue to function once the redox state of the cell returns to normal.
Alterations in another glycolytic enzyme, α-enolase, were identified, which
continues to implicate the loss of ATP production as a viable mechanism for
neurodegeneration. Currently, three isoforms of enolase are known, α-, β-, and γ-enolase.
Enolase exists as homodimers or heterodimers. Previous studies recognized α-enolase as
oxidatively modified with diminished activity in AD hippocampus compared to agematched controls (Castegna et al. 2002a; Meier-Ruge et al. 1984; Schonberger et al.
2001). Results from this present dissertation research confirms that α-enolase is also Sglutathionylated in IPL region of the AD brain and that the activity is diminished. Sglutathionylated α-enolase performs at a reduced rate (Figure 6.3). This activity can be
recovered if the cell returns to a normal redox state (Beer et al. 2004). α-enolase is a
highly conserved cytoplasmic glycolytic enzyme that catalyzes the formation of
phosphoenolpyruvate from 2-phosphoglycerate. This high-energy intermediate propels
the generation of ATP in glycolysis (Harris et al. 1976). This study is consistent with the
decrease in glucose metabolism in the AD pathology with α-enolase oxidation and
activity decline.
Oxygen is used in the breakdown of glucose, i.e., oxygen is critical to energy
production in the brain via glucose and consequent neuron survival. Deoxyhemoglobin is
the counterpart to oxyhemoglobin that carries the blood back to the heart once the blood
has been deoxygenated. Previous studies showed patients with AD dementia have a
decreased cerebral blood flow indicating that neurons could be receiving less oxygen and
therefore producing less energy (Haxby et al. 1988). Our studies are consistent with these
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findings by distinguishing the protein deoxyhemoglobin as oxidatively modified in the
AD IPL as compared to age-matched controls. This alteration could change the way
hemoglobin functions, decreasing its ability to supply oxygen to neurons in the brain.
Irregularity in energy metabolism, which could be initiated by a decrease in oxygen
consumption, is characterized in the AD brain (Butterfield and Boyd-Kimball 2004a).
The specific modification to the β chain of hemoglobin reported in this study is Sglutathionylation. The effects on the attachment of glutathione have been previously
investigated resulting in an increase in affinity for oxygen, a reduction in the Bohr effect,
and oxidation of the protein (Wodak et al. 1986). The increase in affinity for oxygen
consequently reduces the oxygen release, and contributes to a decline in ATP production.
The alkaline Bohr effect was also reduced by 38% in AD brain, which demonstrated a
decrease in pH dependence on oxygen affinity (Craescu et al. 1986). The increase in Sglutathionylation of hemoglobin likely decreases energy production and mechanistically
contributes to the pathology of AD.
α-Crystallin B is a small heat shock protein (sHSP) that functions as a heat
inducible chaperone. α-Crystallin B has been found to be elevated in AD brain and codeposited with Aβ in SP (Hoshi and Tamura 1993; Ingvar and Schwartz 1974). SP
resident, Aβ(1-42) has demonstrated a toxic characteristics with the ability to induce
oxidative damage to neuronal proteins (Boyd-Kimball et al. 2004). If α-Crystallin B is
co-deposited with Aβ(1-42), then it is conceivable that this protein would be oxidatively
modified in the AD brain, consistent with this study. It can also be predicted that there
would be an increase in expression since α-Crystallin B is a stress-inducible chaperone.
Protein oxidation leads to dysfunction, and a decreased performance of α-Crystallin B
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that could cause an increase in misfolded proteins in AD pathology (Raman et al. 2005).
Previous studies have shown that α-Crystallin B actually protects anti-oxidant enzymes
from oxidation during acute inflammation (Masilamoni et al. 2005). Other studies also
link α-Crystallin B with reduced thiol oxidation of other lens crystallins during oxidative
stress, which could be an explanation for its own thiol oxidation. Often in thiol
oxidation-reduction reactions, to reduce one thiol group another thiol group is oxidized.
Once oxidized this would make α-Crystallin B a S-glutathionylation target.
In conclusion, this study reports that specific proteins have an increased Sglutathionylation in the AD brain when compared to age-matched controls. The exact
function of this reversible oxidative modification is unknown. The activity of Sglutathionylated enzymes is diminished, but studies show that the activity can be
recovered in reducing conditions. Further studies investigating the specific in vivo effects
of S-glutathionylation in oxidative stress are important to determine the role of Sglutathionylation in the AD brain.

Copyright © Shelley Faye Newman 2008
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Chapter Seven
Idenification of S-glutathionylated proteins in the early Alzheimer's disease inferior
parietal lobule as compared to control, a proteomics approach.
7.1 Introduction
7.1.1 Early Alzheimer’s disease
The progression of Alzheimer’s disease (AD) is documented at 3 stages, Mild
Cognitive Impairment (MCI), particularly amnestic MCI, Early AD (EAD), and latestage AD (LAD). The previous study was conducted from the inferior parietal lobule
(IPL) of subjects with LAD, however, there is little documented information about EAD,
though previous evidence has shown an increase in oxidative damage IPL of the EAD
brain (Williams et al. 2006, Reed et al. 2008). Specifically, using redox proteomics, our
laboratory identified IPL proteins with increased nitration of peroxiredoxin 2, triose
phosphate isomerase, glutamate dehydrogenase, neuropolypeptide h3, phosphoglycerate
mutase1, H(+) -transporting ATPase, alpha-enolase, and fructose-1,6-bisphosphate
aldolase (Reed et al. 2008). In this disseration study, proteomics was used to identify
IPL proteins in subjects with EAD that had elevated S-glutathionylation compared to
control.
7.2 Experimental Procedure
7.2.1 EAD and Control Subjects
The samples used for this study were obtained from the inferior parietal lobule (IPL) of
four EAD subjects with four age-matched controls. The autopsy samples had average
postmortem intervals (PMIs) of 2.9 h for EAD subjects and 2.4 h for EAD control
samples were provided by the Rapid Autopsy Program of the University of Kentucky
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Alzheimer’s Disease Clinical Center (UK ADC) Demographics are shown in Table 7.1.
All of the control subjects had no cognitive complaints, normal neuropsychological test
scores, intact activities of daily living (ADLs), and normal neurologic examinations. The
control subjects also showed no significant histopathological markers with an average
Braak score of 1.1. The criteria for EAD were a decline in cognitive function from a
previous higher level, impairment in one or more areas of cognition in addition to
memory, altered activities of daily living, a clinical dementia rating (CDR) score of 0.5
to 1.0, and a clinical evaluation that revealed no other cause for the dementia.
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Table 7.1
Demographic Data of EAD and Control Subjects (Mean ± S.D.)
Samples
(n = 4)

Age
(years)

Control

79 ± 2.4

EAD

86 ±4.0

Gender

Brain Weight Post Mortem
Mean
(g)
Interval (h) Braak Stage

Male: Female
(2:2)
Male: Female
(1:3)

1250 ±57

2.9 ±0.4

1.5

1220±41

2.4 ±0.3

5.0

Abbreviations: AD, Alzheimer’s disease; S.D., Standard deviation; n, number of
individuals
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7.2.2 Sample Preparation
Samples were prepared as described in section 6.2.2 of this dissertation.
7.2.3 Two-dimensional Electrophoresis
Proteins were separated using the same protocol as described in section 6.2.3 of this
dissertation.
7.2.4 Two-Dimensional Western Blotting
Proteins were transferred from the 2D gel to the 2D blot as described in section 6.2.4 of
this dissertation.
7.2.5 Image Analysis
The image analysis was completed as detailed in section 5.2.5 of this dissertation.
7.2.6 In-Gel Trypsin Digestion
The in-gel trypsin digestion was carried out with the same protocol as described in
section 5.2.6 of this dissertation.
7.2.7 Mass Spectrometry
The peptide mass fingerprint was determined using the same protocol as described in
section 5.2.7 of this dissertation.
7.2.8 Protein Identification
Proteins were identified using the Mascot search engine as described in section 5.2.8 of
this dissertation.
7.2.9 Enzymatic Activity
The specific activity of α-enolase was determined using the protocol described in section
6.2.9 of this dissertation.
7.2.10 Statistical Analysis
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The data were analyzed as described in section 6.2.10 of this dissertation.

7.3 Results
7.3.1 Identification of Specific S-Glutathionylated Proteins in EAD
In this study specific proteins were identified to have a significant increase in Sglutathionylation in the EAD IPL as compared to age-matched, cognitively normal
controls. S-glutathionylated proteins were identified by comparative analysis on the
images of the 2D blots and gels using PD Quest software. Each individual protein spot
on the 2D blot was normalized to the amount of protein in the 2D gel (Fig. 7.1). This
analysis verified that not all of the protein spots with increased immunoreactivity are due
an increase in S-glutathionylation, but the increased immunoreactivy correlates to an
increase in protein expression in the brain (Castegna et al. 2002b; Castegna et al. 2002a;
Poon et al. 2004). The analysis of the 2D blots of EAD IPL detected four significantly
increased S-glutathionylated protein spots compared to those of age-matched control IPL
(Fig. 7.1). The percent increase of S-glutathionylation of each protein along with their
significance is reported in Table 7.2. The protein spots of interest were subjected to
mass analysis using MALDI mass spectrometry for protein identification after in-gel
trypsin digestion. The Mascot search engine successfully identified the four modified
proteins in EAD using their peptide mass fingerprint determined by mass spectrometry to
be dimethylarginine dimethylaminohydrolase (DDAH), cathepsin B, 14-3-3 γ, and γenolase. Table 7.3 provides data for protein identification including the peptides
matched, percentage coverage, and pI and Mr values.
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Figure 7.1

Figure 7.1 The proteins from EAD and age-matched controls were separated using 2D
electrophoresis. The gels are then stained with SYPRO Ruby stain. An example
control and EAD gel is displayed at the bottom of the figure. 2D-oxyblots,
demonstrate the immunochemical detection of glutathionylated proteins. An
example control and EAD blot is presented at the top of the figure. The protein
spots are labeled with the proteins identified in this study.
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Table 7.2
Summary of Identified S-glutathionylated Proteins in EAD IPL
Protein

p value

γ-enolase

Protein Oxidation
(% Control ± SEM)
190±13.2

Cathepsin D

347±12.3

< 0.04

DDAH

353±4.0

< 0.01

14-3-3 γ

990±172

< 0.06

< 0.03

Abbreviations: DDAH, dimethylarginine dimethylaminohydrolase; SEM,
standard deviation of the mean
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Table 7.3
Summary of Glutathionylated Proteins in the EAD IPL Identified with Mass
Spectrometry
Identification
γ-enolase

# Peptides matched of
identified protein
16/31

% Coverage of
matched peptides
52%

pI, Mr
(kDa)
4.91,47.5

Mowse
Score
195

Cathepsin D

9/14

30%

6.10, 45.0

125

DDAH

10/16

41%

5.53, 31.1

144

14-3-3 γ

7/26

27%

4.80, 28.3

65

Abbreviations: DDAH, dimethylarginine dimethylaminohydrolase; pI, isoelectric point;
Mr, relative mobility

90

7.4 Discussion
Previous studies have shown there is a progressive increase in oxidative stress
with the development of Alzheimer’s disease (Butterfield et al. 2007). This also
correlates with an increase in oxidized proteins from MCI to AD (Butterfield et al. 2007).
Oxidatively modified proteins generally demonstrate impaired protein function resulting
in neuronal death, which is consistent with AD pathology (Hensley et al. 1995;
Lauderback et al. 2003; Butterfield and Boyd-Kimball 2004). A number of oxidatively
modified proteins have been identified using redox proteomics as oxidized in MCI and
AD brain (Castegna et al. 2002b; Castegna et al. 2002a; Castegna et al. 2003; Sultana et
al. 2006d; Sultana et al. 2006a; Sultana et al. 2006c). These proteins are involved in
energy metabolism, mitochondrial function, cell cycle, synaptic plasticity, excitotoxicity,
proteasome dysfunction, lipid abnormalities, neuritic abnormalities, tau
hyperphosphorylation, etc. (Castegna et al. 2002b; Castegna et al. 2002a; Butterfield and
Boyd-Kimball 2004; Sultana et al. 2005b; Sultana et al. 2005a; Sultana et al. 2006a).
These processes are all adversely affected in AD pathology, so the loss of protein
function due to oxidation could be a plausible mechanism for neurodegeneration in the
AD brain.
An endogenous protection mechanism against oxidative damage in brain in
glutathione, GSH. GSH is a recyclable antioxidant (Klatt and Lamas 2000). In oxidative
conditions, GSH reacts with oxidized cysteine residues of proteins as a transient
modification, S-glutathionylation. The purpose of this modification is not fully
elucidated, though it could potentially serve as protection from irreversible oxidation of
cysteine residues (Souza and Radi 1998; Baty et al. 2005) or activation of oxidatively
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sensitive signaling pathways (Thomas et al. 1995; Yang et al. 2002; Dalle-Donne et al.
2003). A previous study by Dalle-Donne et al. gives some indication of the mechanism
of S-glutathionylation. These authors observed that S-glutathionylated actin had reduced
activity, which was then be reversed with reduced GSH (Dalle-Donne et al. 2003). In a
previous study from our laboratory, we identified the specific targets of Sglutathionylation in AD IPL when compared to age-matched controls revealing the Sglutathionylation of GAPDH, hemoglobin, crystalline B, and α-enolase. Both GAPDH
and α-enolase in the AD IPL brain were analyzed to determine effects on enzymatic
activity and both showed significantly decreased activity. These data led us to the
current study to determine S-glutathionylation in EAD IPL, and if this post-translational
modification could provide insight into earlier steps in the pathogenesis of AD.
The analysis of S-glutathionylated EAD IPL brain proteins, identified four
significantly S-glutathionylated proteins in the EAD brain compared to age-matched
controls: 14-3-3γ, cathepsin B, DDAH, and γ-enolase. All of these proteins have been
linked with the pathogenesis of AD. 14-3-3γ is involved with regulation of
phosphorylation of tau and is deposited in the NFT’s in AD brain (Layfield et al. 1996;
Umahara et al. 2004). 14-3-3γ regulates glycogen synthase kinase 3 beta (GSK 3β) and
there are hypotheses as to how 14-3-3γ is involved in this process (Matthews and
Johnson 2005; Li and Paudel 2007). The oxidation of 14-3-3γ is documented in the AD
brain (Santpere et al. 2007) as well as direct oxidation by Aβ (1-42) (Boyd-Kimball et
al. 2005; Sultana et al. 2006b). 14-3-3γ is also involved in an apoptotic pathway.
Neuronal death is characteristic of the AD brain, for which apoptosis is thought to
contribute (Nunomura et al 2007). 14-3-3γ has anti-apoptotic properties by regulating
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Bad, which initiates the release of cytochrome c and the caspade cascade. If Sglutathionylation reduces the activity of an enzyme then it is possible that the Sglutathionylation of 14-3-3γ decreases its inhibition of Bad thereby increasing apoptosis
and leading to neuronal death.
DDAH is involved in the regulation of nitric oxide synthesis by breaking down
asymmetric dimethyl arginine that inhibits neuronal nitric oxide synthesis (MacAllister et
al., 1996) DDAH in its normal state increases the production of nitric oxide. Nitric
oxide synthase in the AD brain is upregulated, increasing nitric oxide, which inhibits
DDAH. Nitric oxide is important to the function of NMDA receptors and neuronal
communication. If DDAH is inhibited by S-glutathionylation then it could affect
synaptic function that is consistent with AD. Earlier redox proteomics analysis identified
DDAH as oxidatively modified in brain in familial AD (Butterfield et al. 2006).
Cathepsin B is found to be co-localized with apo E in SP of the AD brain (Zhou
et al. 2006). Cathepsin B degrades Aβ, possibly explaining its translation to SP and its
proximity to Aβ is consistent with the notion that cathepsin B could be oxidized in the
AD brain. The S-glutathionylation of cathepsin B conceivably could be in response to
oxidation caused by Aβ, and hormone response needed to protect cathepsin B, as Sglutathionylation is a direct protective mechanism against Aβ. S-glutathionylation,
though protective against irreversible oxidative damage generally does reduce enzymatic
activity slowing the degradation of Aβ. This scenario is consistent with increased Aβ in
the AD brain.
Enolase was shown to have a significant increase in S-glutathionylation in both
the EAD and AD IPL. Alterations this glycolytic enzyme, implicates the loss of ATP
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production as a viable mechanism for neurodegeneration. Previous studies recognized αenolase as oxidatively modified with diminished activity in AD hippocampus and IPL
compared to age-matched controls (Castegna et al. 2002a; Meier-Ruge et al. 1984;
Schonberger et al. 2001, Newman et al. 2007). α-enolase is a highly conserved
cytoplasmic glycolytic enzyme that catalyzes the formation of phosphoenolpyruvate
from 2-phosphoglycerate. This high-energy intermediate propels the generation of ATP
in glycolysis (Harris et al. 1976). This study continues to be consistent with the decrease
in glucose metabolism in the AD pathology, α-enolase oxidation, and activity decline.
14-3-3 γ, DDAH, and cathepsin B were identified as S-glutathionylated in EAD
IPL, but not in the AD IPL. One possible explanation for the difference between EAD
and AD, is that the oxidative conditions in late – stage AD brain are so severe that the
cysteines may have been irreversibly oxidized making them no longer susceptible to Sglutathionylation. For example, cathepsin B is in close proximity to Aβ, so as the
concentration of Aβ increases with the progression of AD, this could lead to cysteinic
acid, which would not be identified using the antibody to determine S-glutathionylation.

Copyright © Shelley Faye Newman 2008
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Chapter Eight
Identification of S-glutathionylated proteins in the mild cognitive impairment
inferior parietal lobule as compared to control, a proteomics approach
8.1 Introduction
8.1.1 Mild Cognitive Impairment
Amnestic mild cognitive impairment (MCI) is a transitional condition between
normal aging and early-stage Alzheimer’s disease (EAD) (Markesbery et al. 2006).
Individuals with amnestic MCI are at an increased risk of developing AD with a rate of
progression between 10% and 15% per year (Petersen et al. 1999; Petersen et al. 2001).
Amnestic MCI is described as a condition with a subtle but measurable memory disorder
not associated with dementia (Markesbery et al. 2006). Though MCI arguably is the
earliest form of AD (Petersen et al. 2001), the initial origin of AD pathogenesis has not
been elucidated, but it is apparent that oxidative stress is implicated in the progression of
AD (Butterfield and Stadtman 1997; Markesbery 1997; Butterfield 2002; Butterfield et
al. 2007a).
Oxidative stress is caused by a shift in the oxidation-reduction status of the cell,
which produces oxidative damage such as protein oxidation, lipid peroxidation, DNA
oxidation, advanced glycation end products, reactive oxygen species (ROS), and reactive
nitrogen species (RNS) formation (Butterfield and Stadtman 1997). ROS and RNS can
lead to additional impairment of cellular function by directly modifying proteins and
activate oxidatively-sensitive pathways (Smith et al. 1994; Markesbery 1997; Butterfield
and Kanski 2001; Lovell et al. 2001; Butterfield and Lauderback 2002).
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8.2 Experimental Procedure
8.2.1 MCI and Control Subjects
The samples used for this study were obtained from the inferior parietal lobule (IPL) of
five MCI patients with five aged-matched controls. The autopsy samples had average
postmortem intervals (PMIs) of 3.13 h for MCI patients, and 2.88 h for MCI control
subjects provided by the Rapid Autopsy Program of the University of Kentucky
Alzheimer’s Disease Clinical Center (UK ADC). Demographics of subjects are listed in
Table 1. All of the control subjects had no cognitive complaints, normal
neuropsychological test scores, intact activities of daily living (ADLs), and normal
neurologic examinations. The control subjects also showed no significant
histopathological markers with an average Braak score of 1.1. The amnestic MCI
patients were diagnosed according to the criteria described by Petersen and coworkers
(Petersen et al. 1999), which included: a memory complaint supported by an informant,
objective memory test impairment (age- and education-adjusted), general normal global
intellectual function, intact ADLs, Clinical Dementia Rating score of 0.0 to 0.5, no
dementia, and a clinical evaluation that revealed no other cause for memory decline. The
MCI patients had an average Braak score of 4.0.
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Table 8.1
Demographic Data of MCI and Control Subjects (Mean ± S.D.)
Samples
(n = 6)

Age
(years)

Control

82±2.6

MCI

88±1.5

Gender

Brain Weight Post Mortem
Mean
(g)
Interval (h) Braak Stage

Male: Female
(2:4)
Male: Female
(2:4)

1253±44

2.88±0.5

1.3

1122±25

3.13±0.4

3.8

Abbreviations: MCI, Mild cognitive impairment; S.D., Standard deviation; n, number
of individuals
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8.2.2 Sample Preparation
Samples were prepared as described in section 6.2.2 of this dissertation.

8.2.3 Two-dimensional Electrophoresis
Proteins were separated using the same protocol as described in section 6.2.3 of this
dissertation.

8.2.4 Two-Dimensional Western Blotting
Proteins were transferred from the 2D gel to the 2D blot and detected as described in
section 6.2.4 of this dissertation.

8.2.5 Image Analysis
The image analysis was completed as detailed in section 5.2.5 of this dissertation.

8.2.6 In-Gel Trypsin Digestion
The in-gel trypsin digestion was carried out with the same protocol as described in
section 5.2.6 of this dissertation.

8.2.7 Mass Spectrometry
The peptide mass fingerprint was determined using the same protocol as described in
section 5.2.7 of this dissertation.
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8.2.8 Protein Identification
Proteins were identified using the Mascot search engine as described in section 5.2.8 of
this dissertation.

8.2.9 Enzymatic Activity
The specific activity of α-enolase was determined using the protocol described in section
6.2.9 of this dissertation.

8.2.10 Statistical Analysis
The data was analyzed as described in section 6.2.10 of this dissertation.

8.3 Results
8.3.1 Identification of Specific S-Glutathionylated Proteins in MCI IPL
In this study specific proteins were identified to have a significant increase in Sglutathionylation in the MCI IPL as compared to the respective age-matched, cognitively
normal controls. S-glutathionylated proteins were identified by comparative analysis on
the images of the 2D blots and gels using PD Quest software. Each individual protein
spot on the 2D blot was normalized to the amount of protein in the 2D gel (Fig. 8.1). This
analysis verified that not all of the protein spots with increased immunoreactivity are due
an increase in S-glutathionylation, but the increased immunoreactivy correlates to an
increase in protein expression in the brain (Castegna et al. 2002b; Castegna et al. 2002a;
Poon et al. 2004).
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The analysis of the 2D blots of MCI IPL detected one significantly increased Sglutathionylated protein spot when compared to the age-matched control IPL, α-enolase
(Fig. 8.1). The identified protein with elevated S-glutathionylation in MCI is reported in
Table 8.2 as a percent increase. The protein spot of interest was subjected to mass
analysis using MALDI mass spectrometry for protein identification after in-gel trypsin
digestion. The Mascot search engine successfully identified the one significantly
modified protein in MCI as α-enolase. Table 8.3 provides data for protein identification
including the peptides matched, percentage coverage, and pI and Mr values.
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Figure 8.1

Figure 8.1 The proteins from MCI and age-matched controls were separated using 2D
electrophoresis. The gels are then stained with SYPRO Ruby stain. An example
control and MCI gel is displayed at the bottom of the figure. 2D-oxyblots,
demonstrate the immunochemical detection of glutathionylated proteins. An
example control and MCI blot is presented at the top of the figure. The protein
spots are labeled with the proteins identified in this study.
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Table 8.2
Summary of Identified S-glutathionylated Proteins in MCI IPL
Protein
α-enolase

Protein Oxidation
(% Control ± SEM)
279±0.85

Abbreviations: SEM, standard deviation of the mean
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p value
< 0.03

Table 8.3
Summary of Glutathionylated Proteins in the MCI IPL Identified with Mass
Spectrometry
Identification
α-enolase

# Peptides matched of
identified protein
11/36

% Coverage of
matched peptides
36%

Abbreviations: pI, isoelectric point; Mr, relative mobility
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pI, Mr
(kDa)
6.99,47.4

Mowse
Score
102

8.3.2 Enzymatic Activity of α-enolase
The measurement of enzymatic activity of enolase (Fig. 8.2) from MCI IPL
revealed decreased activity compared to the age-matched control. A comparison between
the previously reported oxidized proteins in AD IPL (Castegna et al. 2002a; Castegna et
al. 2002b) and the currently identified S-glutathionylated proteins in MCI IPL revealed αenolase as oxidatively modified in both studies. This is also consistent with the increased
S-glutathionylation and reduced activity of α-enolase in the AD IPL.
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Figure 8.2

Figure 8.2: The measurement of enolase enzyme assay was performed as described in the
“Experimental Procedures” section. The age-matched control and MCI IPL
samples were the same that were used for redox proteomics. The data are the
mean ± SEM expressed as units per ml. Statistical comparison was made using
two-tailed Student’s t-tests. (n=5). (*)<0.05, MCI vs. Age-matched control
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8.4 Discussion
Oxidative stress occurs with the development of Alzheimer’s disease (Butterfield
et al. 2007a), which also correlates with an increase in oxidized proteins from MCI to
AD (Butterfield et al. 2007a). Oxidatively – modified proteins demonstrate impaired
protein function resulting in neuronal death, consistent with AD pathology (Hensley et
al. 1995; Lauderback et al. 2003; Butterfield and Boyd-Kimball 2004). Oxidatively –
modified proteins have been identified using redox proteomics as oxidized in MCI and
AD brain (Castegna et al. 2002b; Castegna et al. 2002a; Castegna et al. 2003; Sultana et
al. 2006; Butterfield et al. 2007a; Butterfield et al. 2007b). These proteins are involved
in energy metabolism, mitochondrial function, Aβ production, cell cycle, synaptic
plasticity, excitotoxicity, proteosomal dysfunction, lipid abnormalities, neuritic
abnormalities, tau hyperphosphorylation, etc. (Castegna et al. 2002b; Castegna et al.
2002a; Butterfield and Boyd-Kimball 2004; Sultana et al. 2005b; Sultana et al. 2005a;
Sultana et al. 2006). These processes are all adversely affected in AD pathology, so the
loss of protein function due to oxidation could be a plausible mechanism for
neurodegeneration in the AD brain.
As described previously, glutatione (GSH) is an endogenous recyclable
antioxidant that provides a protection mechanism against oxidative damage in brain
(Klatt and Lamas 2000). In oxidative conditions, GSH reacts with oxidized cysteine
residues of proteins as a transient modification, S-glutathionylation. The purpose of this
modification is not fully understood, though it could potentially serve as protection from
irreversible oxidation of cysteine residues (Souza and Radi 1998; Baty et al. 2005) or
activation of oxidatively sensitive signaling pathways (Thomas et al. 1995; Yang et al.
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2002; Dalle-Donne et al. 2003). The Dalle-Donne laboratory observed that Sglutathionylated actin had reduced activity, which was then be reversed with reduced
GSH (Dalle-Donne et al. 2003). In a previous study from our laboratory, we identified
the specific targets of S-glutathionylation in AD IPL when compared to age-matched
controls revealing the S-glutathionylation of GAPDH, hemoglobin, crystalline B, and αenolase. Both GAPDH and α-enolase in the AD IPL brain were analyzed to determine
effects on enzymatic activity and both showed significant decreased activity. The current
study was used to determine S-glutathionylation through the progression of AD, and if
this post-translational modification could provide insight into the initial steps in the
pathogenesis of AD.
Alterations of the glycolytic enzyme, α-enolase, implicates the loss of ATP
production as a viable mechanism for neurodegeneration. Currently, three isoforms of
enolase are known, α-, β-, and γ-enolase. Enolase exists as homodimers or heterodimers.
Previous studies recognized α-enolase as oxidatively modified with diminished activity
in AD hippocampus compared to age-matched controls (Castegna et al. 2002a; MeierRuge et al. 1984; Schonberger et al. 2001). Results from this inquiry confirms that αenolase is also S-glutathionylated in IPL region of the MCI brain and that the activity
continues to be depleted. S-glutathionylated α-enolase performs at a reduced rate (Figure
8.2). This activity can be recovered if the cell returns to a normal redox state (Beer et al.
2004). α-enolase is a highly conserved cytoplasmic glycolytic enzyme that catalyzes the
formation of phosphoenolpyruvate from 2-phosphoglycerate. This high-energy
intermediate propels the generation of ATP in glycolysis (Harris et al. 1976). This study
is consistent with the decrease in glucose metabolism in the AD pathology.
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Chapter Nine
Increased carbonylated proteins in the early Alzheimer's disease inferior parietal
lobule identified using redox proteomics
9.1 Introduction
9.1.1 Early Alzheimer’s disease
The progression of Alzheimer’s disease (AD) is documented in three stages: mild
cognitive impairment (MCI), early AD (EAD), and late-stage AD (LAD). Previous
redox proteomics studies were conducted on the inferior parietal lobule (IPL) and
hippocampus of subjects with LAD {Castegna, 2002 #9; Castegna, 2002 #8; Sultana,
2006 #156}. There is little documented information about EAD, though previous
evidence has shown an increase in oxidative damage IPL of the EAD brain (Williams et
al. 2006; Reed et al. 2008). Specifically, the Butterfield laboratory reported proteomics –
determined increased nitration of peroxiredoxin 2, triose phosphate isomerase, glutamate
dehydrogenase, neuropolypeptide h3, phosphoglycerate mutase1, H(+) -transporting
ATPase, alpha-enolase, and fructose-1,6-bisphosphate aldolase in EAD brain (Reed et al.
2008).
9.2 Experimental Procedure

9.2.1 EAD and Control Subjects
The samples used for this study are the same samples that were described in the 7.2.1 of
this dissertation and are listed in Table 9.1.
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Table 9.1
Demographic Data of EAD and Control Subjects (Mean ± S.D.)
Samples
(n = 4)

Age
(years)

Control

79 ± 2.4

EAD

86 ±4.0

Brain Weight Post Mortem
Mean
(g)
Interval (h) Braak Stage

Gender
Male: Female
(2:2)
Male: Female
(1:3)

1250 ±57

2.9 ±0.4

1.5

1220±41

2.4 ±0.3

5.0

Abbreviations: AD, Alzheimer’s disease; S.D., Standard deviation; n, number of
individuals
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9.2.2 Sample Preparation
Samples were prepared as described in section 6.2.2 of this dissertation.
9.2.3 Two-dimensional Electrophoresis
Samples were separated using the protocol described in section 5.2.3 of this dissertation.

9.2.4 Two-Dimensional Western Blotting
Proteins were transferred from the 2D gel to the 2D blot and detected as described in
section 5.2.4 of this dissertation.

9.2.5 Image Analysis
The image analysis was completed as detailed in section 5.2.5 of this dissertation.

9.2.6 In-Gel Trypsin Digestion
The in-gel trypsin digestion was carried out with the same protocol as described in
section 5.2.6 of this dissertation.

9.2.7 Mass Spectrometry
The peptide mass fingerprint was determined using the same protocol as described in
section 5.2.7 of this dissertation.

9.2.8 Protein Identification
Proteins were identified using the Mascot search engine as described in section 5.2.8 of
this dissertation.
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9.2.9 Statistical Analysis
The data was analyzed as described in section 6.2.10 of this dissertation.

9.3 Results

9.3.1 Identification of Specific Carbonylated IPL Proteins in EAD
Two-dimensional (2D) electrophoresis offers an efficient tool for screening for
abundant protein changes in different disease states as well as differences in metabolic
pathways, (Butterfield et al. 2003; Butterfield and Castegna 2003). In this dissertation
research a parallel approach to quantify the protein levels by SYPRO Ruby staining and
the carbonyl levels by immunohistochemistry was used (Figure 9.1). SYPRO Ruby
fluorescent stain achieves a linear and sensitive staining of gel slabs, and immunoblotting
with antibody against protein – bond DNP hydrazone allows specific detection of DNPadducts in brain samples. The specific carbonyl levels were obtained by dividing the
carbonyl level of a protein spot on the nitrocellulose membrane by the protein level of its
corresponding protein spot on the gel. Such numbers give the carbonyl level per unit of
protein, correcting for a change in protein concentration.
The comparison of EAD IPL samples versus age-matched control IPL samples
can be seen with representative SYPRO Ruby stained 2D gels and immunochemically
detected DNP blots (Figure 9.1). The comparative analysis of these blots and gels
identified three proteins as significantly more oxidized: fructose bisphosphate aldolase C
(FBA-C), phosphoglycerate mutase 1 (PM-1), and glial fibrillary acidic protein (GFAP)
seen in Table 9.2. These proteins were identified by mass spectrometry analysis and
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database searching. The criteria of this identification can be found in Table 9.3
including: peptides matched, percentage coverage, pI, MW values and the increase of
specific carbonyl levels, indexed as percentage of control.
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Figure 9.1

Figure 9.1 The proteins from EAD and age-matched controls were separated using 2D
electrophoresis. The gels are then stained with SYPRO Ruby stain. An example
control and EAD gel is displayed at the bottom of the figure. 2D-oxyblots,
demonstrate the immunochemical detection of carbonylated proteins. An example
control and EAD blot is presented at the top of the figure. The protein spots are
labeled with the proteins identified in this study.
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Table 9.2
Summary of Identified Carbonylated Proteins in EAD IPL
Protein

Protein Oxidation
p value
(% Control ± SEM)
FBA-C
19500 ± 7616
p < 0.05
PM-1
409 ± 113
p < 0.05
GFAP
44400 ± 166
p < 0.05
Abbreviations: FBA-C, Fructose bisphosphate aldolase C; PM-1,
Phosphoglycerate mutase 1; GFAP, glial fibrillary acidic protein; SEM, standard
deviation of the mean
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Table 9.3
Summary of Carbonylated Proteins in the EAD IPL Identified with Mass
Spectrometry
Identification
FBA-C

# Peptides matched
of identified protein
14/33

% Coverage of
matched peptides
49%

pI, Mr
(kDa)
6.46, 39.7

Mowse
Score
166

PM-1

8/21

39%

6.75, 28.8

96

GFAP

15/41

41%

5.42, 49.9

120

Abbreviations: FBA-C, Fructose bisphosphate aldolase C; PM-1, Phosphoglycerate
mutase 1; GFAP, glial fibrillary acidic protein; pI, isoelectric point; Mr, relative mobility
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9.4 Discussion
Previous studies have shown that energy metabolism is affected in AD and has even
been shown to be oxidatively modified early in the progression of the disease i.e., in
MCI{Butterfield, 2007 #466; Butterfield, 2006 #294; Butterfield, 2007 #293; Castegna,
2002 #9; Castegna, 2002 #8; Castegna, 2003 #31; Sultana, 2006 #134; Sultana, 2006
#148}. This study extends these prior studies, as both PM-1 and FBA-C are metabolic
enzymes. PM-1, a glycolytic enzyme, catalyzes the interconversion of 3phosphoglycerate to 2-phosphoglycerate in a reaction that results in the production one
equivalent of ATP. Previous studies have shown that the enzymatic activity of PM-1 is
decreased in AD {Iwangoff, 1980 #477} resulting in protein dysfunction and therefore
increased glycolytic intermediates, reduced pyruvate production, and decreased ATP
production.
FBA-C, another glycolytic enzyme, catalyzes the cleaveage fructose-1,6 bisphosphate into dihydroxyacetone phosphate (DHAP) and glycerate-3-phosphate.
Previous studies showed a significant decrease in the level of FBA-C are in the AD
hippocampus {Sultana, 2007 #478} and oxidatively-modified in a mouse model of aging
{Vaishnav, 2007 #479}. Oxidative modifications generally inhibit enzyme activity,
which in this case would result in increased levels of fructose 1,6- bisphosphate,
inhibition of complete glycolysis, and ATP depletion.
GFAP is found exclusively in astrocytes and has been shown to undergo activation
in AD conditions {Gu, 2008 #480}. The current results were consistent with the
previous study and show that GFAP undergoes oxidation early in the progression of AD,
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consistent with an ongoing inflammatory process.
While EAD is relatively early in the development of AD, the oxidized proteins are
in line with protein modifications found later in the disease. The ability to alter the
oxidation of these proteins and their ramifications could provide links to potential
therapeutic options.

Copyright © Shelley Faye Newman 2008
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Chapter Ten
Conclusions and Future Studies
10.1 Conclusion
In this dissertation I have demonstrated that during the progression of
Alzheimer’s disease (AD) proteins undergo S-glutathionylation as a post-translational
modification likely due to increased oxidation present. Previous studies have shown that
oxidation increases with the development of AD and that as a result of oxidation there is
a shift in the ratio of reduced and oxidized glutathione (GSH:GSSG) towards GSSG. An
increase in oxidative conditions activates glutathione –S – transferase (GST) transferring
GSH to oxidized proteins producing S-glutathionylated proteins; however, when GST is
oxidized it loses its function. This limits the reduction of S-glutathionylated proteins in
late-stage AD.
Studying the S-glutathionylation of proteins in the progression of AD identified
one common modified protein throughout the progression of AD, enolase. Enolase is
commonly known as a metabolic enzyme in glycolysis. Enolase catalyzes the reaction of
2-phosphoglycerate to phosphoenolpyruvate, which is the substrate to the final reaction
of glycolysis producing 2 equivalents of ATP. The reduction in enolase activity
significantly debilitates energy production, which is documented in AD brain.
S-glutathionylation is a transient post-translational modification, meaning that it
creates no permanent damage to the protein unless the mechanism of removal has been
inhibited. Interest in this protein modification was peaked at the potential to determine
proteins modified early in the development of AD that could be reversed to recover
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protein function. Using a glutathione mimetic as a therapeutic could shift the
GSH:GSSG ratio recovering the redox status of a normal cell.
Tricyclodecan-9-yl-xanthogenate (D609) is a glutathione mimetic shown to have
antioxidant properties in Aβ - treated neuronal cells. This ability is tied to its ability to
reduce an oxidant and then be recycled by glutathione reductase (GR) back to its reduced
form. Proteomics studies showed that D609 not only protects against oxidation on a
global level, but that it also protects specific proteins against oxidation. Glyceraldehyde3-phospate (GAPDH), 14-3-3 zeta, pyruvate kinase, and malate dehydrogenase were
protected against Aβ - induced oxidation with a pretreatment of D609, all of which have
been previously shown to be modified in the AD brain. Providing evidence that the
D609 given as an antioxidant could potentially protect against specific protein oxidation
in the AD brain.
Without an antioxidant treatment, oxidative damage occurs early in the
progression of the disease. This dissertation demonstrated there is a significant protein
carbonylation in early Alzheimer’s disease (EAD), which is an oxidative modification.
Even more than an increase in global oxidation; fructose bisphosphate aldolase C (FBAC), phosphoglycerate mutase 1 (PM-1), and glial fibrillary acidic protein (GFAP) show a
significant increase in protein carbonylation. This finding further proves that oxidative
damage is not only a characteristic of late stage AD, but progresses with the development
of the disease making it all the more important to have preventative measures against
oxidation. Augmenting the GSH:GSSG ratio with a GSH mimetic to maintain the redox
status of the cell conceivably could protect neurons from degeneration caused by
oxidation in the AD brain.
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10.2 Future Studies
Based on the results of this dissertation, these following experiments could be
completed to further explore the effects of glutathione in the progression of AD and the
use of D609 as a therapeutic treatment for AD.
1. Further investigation of S-glutathionylation and its effects on enzymatic function in
a system with an alterable redox status to determine at what point the enzymatic
function can not be recovered, specifically of protein altered in the progression of
AD, such as enolase and GAPDH.
2. Using S-glutathionylation to study other regions of the AD brain to determine the
timeline of this oxidative modification with pathogenesis of the disease.
3. Further testing of D609 using in vivo models of AD to determine how well D609
passes through the blood brain barrier and is processed in the body.

Copyright © Shelley Faye Newman 2008
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